Maternal metabolic factors and the association with gestational diabetes: A systematic review and meta-analysis

Nahal Habibi, Aya Mousa, Chau Thien Tay, Mahnaz Bahri Khomami, Rhiannon K. Patten, Prabha H. Andraweera, Molla Wassie, Jared Vandersluys, Ali Aflatounian, Tina Bianco-Miotto, Shao J. Zhou, and Jessica A. Grieger

Abstract
Gestational diabetes (GDM) is associated with several adverse outcomes for the mother and child. Higher levels of individual lipids are associated with risk of GDM and metabolic syndrome (MetS), a clustering of risk factors also increases risk for GDM. Metabolic factors can be modified by diet and lifestyle. This review comprehensively evaluates the association between MetS and its components, measured in early pregnancy, and risk for GDM. Databases (Cumulative Index to Nursing and Allied Health Literature, PubMed, Embase, and Cochrane Library) were searched from inception to 5 May 2021. Eligible studies included ≥1 metabolic factor (waist circumference, blood pressure, fasting plasma glucose (FPG), triglycerides, and high-density lipoprotein cholesterol), measured at <16 weeks’ gestation. At least two authors independently screened potentially eligible studies. Heterogeneity was quantified using I². Data were pooled by random-effects models and expressed as odds ratio and 95% confidence intervals (CIs). Of 7213 articles identified, 40 unique articles were included in meta-analysis. In analyses adjusting for maternal age and body mass index, GDM was increased with increasing FPG (odds ratios [OR] 1.92; 95% CI 1.39–2.64, k = 7 studies) or having MetS (OR 2.52; 1.65, 3.84, k = 3). Women with overweight (OR 2.17; 95% CI 1.89, 2.50, k = 12) or obesity (OR 4.34; 95% CI 2.79–6.74, k = 9) also were at increased risk for GDM. Early pregnancy assessment of glucose or the MetS, offers a potential opportunity to detect and treat individual risk factors as an approach towards GDM prevention; weight loss for pregnant women with overweight or obesity is not recommended.

Systematic review registration: PROSPERO CRD42020199225.

KEYWORDS
body mass index, gestational diabetes, glucose, lipids, meta-analysis, metabolic syndrome, pregnancy

Abbreviations: BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; GDM, gestational diabetes; HbA1c, glycated haemoglobin; SBP, systolic blood pressure.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. Diabetes/Metabolism Research and Reviews published by John Wiley & Sons Ltd.

https://doi.org/10.1002/dmrr.3532
Gestational diabetes mellitus (GDM) is defined as the onset or first recognition of glucose intolerance during pregnancy, primarily in the second or third trimester. GDM is one of the most common metabolic complications in pregnancy, affecting 5%–25% of all pregnant women worldwide, depending on screening approaches and diagnostic criteria. GDM has adverse maternal health consequences, including an increased risk for hypertensive disorders of pregnancy, preterm delivery, medicalised delivery, as well as an increased risk for developing type 2 diabetes and cardiovascular events in the first decade following pregnancy. Offspring of mothers with GDM are at greater risk for large for gestational age, respiratory distress syndrome and neonatal hypoglycaemia, and tend to develop type 2 diabetes at younger ages.

Recognised risk factors for GDM include maternal obesity, advanced maternal age, excess gestational weight gain, Asian and African ethnicity, and a history of diabetes. Fasting or postprandial blood glucose may be assessed early, but whether it is a suitable screening test for GDM has not been clarified. Metabolic syndrome is a clustering of cardiovascular risk factors that includes atherogenic dyslipidaemia, raised blood pressure, insulin resistance, and obesity, increasing the risk of cardiovascular disease (CVD) and diabetes by up to 5-fold. In two pregnancy cohorts, Grieger et al. and Schneider et al. showed that MetS, measured in early pregnancy, increased the risk for GDM by 2–4 fold, even after adjusting for body mass index (BMI). Several studies have demonstrated that individual metabolic markers such as raised triglycerides (TG) or low density lipoprotein cholesterol, or reduced high density lipoprotein cholesterol (HDL-C) pose a significant risk for developing GDM. The relationship between MetS or its individual components as a risk factor for GDM is plausible given their shared relationship to future risk of CVD. Importantly, metabolic factors can be modified by diet, lifestyle and pharmacological agents. Consideration of assessing metabolic markers in early antenatal care may provide information about potential future risk for GDM, allowing for early detection and management.

While some systematic reviews have been conducted on similar topics, they did not specifically examine MetS factors, but rather explored biomarkers associated with placental pathology, central obesity, and predictive or diagnostic biomarkers for metabolic diseases. To date, there has been no systematic review or meta-analysis comprehensively evaluating whether MetS or its components, measured in early pregnancy, associate with risk for GDM. This would be important given the current controversies surrounding early screening of GDM using conventional risk factors, and that intervention studies aimed at preventing GDM, predominantly through targeting hyperglycemia, have not been consistently successful. Measurement of MetS or its components may offer a new approach to identify potential risk for GDM, and which could be used as a complementary component to standard routine antenatal care.

The aim of this systematic review and meta-analysis is to comprehensively evaluate the association between MetS and its components, measured in early pregnancy, and risk for GDM.

2 MATERIALS AND METHODS

We performed a systematic review and meta-analysis of epidemiological studies examining the association between components of MetS and risk of GDM. The review was performed according to the PRISMA 2020 Guidelines (Preferred Reporting Items For Systematic Reviews and Meta-analyses). The study protocol was registered on PROSPERO (International Prospective Register of Systematic Reviews) under the identification code: CRD42020199225 and is available online (www.crd.york.ac.uk/prospero).

2.1 Selection criteria and search strategy

Potential studies were identified through electronic database searches on Cumulative Index to Nursing and Allied Health Literature, PubMed, Embase, and the Cochrane database, and manual searches of potentially eligible references in review articles. The search strategy included a combination of subject indexing terms (i.e., MeSH) and free text search terms relating to early pregnancy, prognostic factors, and GDM, along with search filters recommended for prognostic modelling. The search strategy was iteratively developed by Jessica A Grieger and Nahal Habibi in consultation with an academic librarian. The last search was performed on 5 May 2021. The full search strategy is provided in the Supporting Information.

The PICOTS criteria was used to define the aim, search strategy, inclusion and exclusion criteria, that is Population (Pregnant women), Index (Components of the MetS and MetS as a cluster), Comparator (Unexposed group [non GDM women]), Outcome (GDM measured at 24–28 weeks' gestation), Timing (recruitment <16 weeks' gestation), Setting (Antenatal care). The index prognostic factors included the following MetS factors: waist circumference (WC; abdominal obesity), systolic/diastolic blood pressure, glucose, glycated haemoglobin (HbA1c), TG, or HDL-C, and MetS as a cluster. BMI was also examined because the International Diabetes Federation criteria for MetS includes BMI as a surrogate measure for WC. Excluded studies were those examining diagnostic models; animal models; pregnancy outcomes in women after GDM diagnosis; or studies assessing measurements that are not assessed routinely in antenatal care (e.g., using bioelectrical impedance assay).

2.1.1 Core outcomes

The primary outcome was GDM using any diagnostic criteria, measured at 24–28 weeks' gestation.
2.2 Study selection, data collection and risk of bias assessments

All citations were imported into an Endnote file, duplicates were removed, and the remaining articles export into the Rayyan software database for blind screening.\(^{42}\) Title and abstract screening was completed in duplicate by two authors independently (Jessica A. Grieger, Prabha H. Andraweera, Molla Wassie, Mahnaz Bahri Khomami, Tina Bianco-Miotto, Jared Vandersluys, Shao J Zhou, Nahal Habibi, Aya Mousa), and any disagreements were resolved by consensus between the two authors. Where necessary, authors of included articles were contacted to provide missing information and/or unpublished data.

Data extraction was performed by at least two authors independently (Nahal Habibi, Rhiannon K. Patten, Aya Mousa, Chau Thien Tay, Prabha H. Andraweera, Mahnaz Bahri Khomami, Molla Wassie, Jared Vandersluys, Ali Aflatounian), using a specifically designed Microsoft Excel spreadsheet. Cross-checking and resolving of differences were completed by Jessica A. Grieger. Data extraction was guided by CHARMS Data Extraction for Systematic Reviews of Prediction Modelling Studies; a checklist of key items to be extracted from primary studies of prognostic factors.\(^{43}\) Data extraction included: author, year, country; type of study; study population and sample size; study duration and month/year the study was carried out; inclusion criteria; exclusion criteria; GDM diagnosis and time point; exposures in the model; and statistical adjustments. When risk estimates from more than one multivariable analysis were reported, data were extracted from the analysis adjusting for the largest number of confounders. If risk estimates from other routine antenatal factors were reported, only risk estimates related to MetS were extracted. Only standard cut-off values for categorical data were used, for example, the World Health Organization (WHO) categories for BMI. Outcome data reported as odds ratios (OR)/relative risks (RR) and 95% confidence intervals (CIs) were the primary output of interest.

Risk of bias assessment at the study-level was performed independently by two researchers, using the quality in prognostic factor studies (QUIPS) Risk of Bias tool.\(^{43}\) The same two independent authors who completed the data extraction completed the risk of bias for the same set of studies. Domains included study participation; study attrition; prognostic factor measurement; outcome measurement; adjustment for other key prognostic factors; and statistical analysis and reporting. Each domain was judged as low, moderate or high risk, with more weighting given to the domains of ‘Adjustment for other prognostic factors’ and ‘Statistical analysis and reporting’, due to the observational nature of the included studies. Pilot testing was performed using three test articles to ensure consistency between the authors prior to formally commencing risk of bias assessments. For each study, the item scores were collated and an overall risk of bias (low, moderate, and high) was determined.

2.3 Data analysis

All analyses were conducted using Review Manager (V5.4.1). For the primary meta-analyses, studies reporting OR or RR with 95% CIs were analysed as these data are best suited to address questions on prognosis. Data were pooled using the restricted maximum likelihood random-effects models to account for heterogeneity among the studies and outcome measures.\(^{44}\) Unadjusted analyses were firstly reported followed by adjusted analyses with a core set of prognostic covariates (maternal age, maternal BMI, family history of diabetes, ethnicity). As many of the included studies did not adjust for all four covariates, we opted for at least one core covariate in each model.

Heterogeneity was quantified using the \(I^2\) statistic. Significance for heterogeneity was set at \(p < 0.10\), with an \(I^2 > 50\%\) considered to be of relatively high heterogeneity.\(^{45}\) Sources of heterogeneity were explored where outlier study/s were eliminated from the meta-analysis in a series of sensitivity analyses and the effect size was recalculated to determine the influence of those studies.\(^{46}\) We considered outlier studies that had a different direction of effect, a high effect size, or studies judged to be at high risk of bias.\(^{45}\) If \(\geq 10\) studies were available, we assessed publication bias by visual inspection of funnel plots.\(^{47}\) Data reported as mean and SD/SE or 95% CI, or as median and interquartile range were included in the narrative synthesis.

2.4 Patient and public involvement

This study was a systematic review and therefore did not include patients as study participants.

3 RESULTS

3.1 Study selection and characteristics

The systematic search identified 7213 articles of which 106 were duplicates, 7029 were ineligible, leaving 78 articles in the systematic review and 40 articles in the meta-analysis (Figure 1). Characteristics of the included studies are reported in Table 1. The majority of studies were conducted in China (\(k = 18\) studies), USA (\(k = 9\) studies), UK (\(k = 8\) studies), and Australia (\(k = 8\)). Study population sizes ranged from 107 to 132,899 participants.\(^{49}\) Of the 78 studies included, the majority (41.25%) reported on two or more MetS factors. Body mass index was the most common independently assessed risk factor (64.1%), while 10 studies (12.8%) reported on HbA1C and HDL-C.

In meta-analysis, the minimum set of confounding variables included were: maternal age for overweight and obesity analyses; maternal age and BMI for fasting plasma glucose (FPG), TG, HbA1c, HDL-C, and MetS analyses; and maternal age, BMI, ethnicity, and family history of diabetes, for systolic blood pressure analyses.
3.2 | Quality assessment

Supporting Information (Table S1) presents the risk of bias using the QUIPS tool for each of the 78 included articles. The overall risk of bias was judged as high for 31 studies (39.7%), moderate for 25 studies (32.0%) and low for 22 studies (28.2%). For individual criteria, 33 studies (42.3%) and 31 studies (39.7%), respectively, were graded as high risk for ‘Adjustment for other prognostic factors’ and ‘Statistical analysis and reporting’. One third of the studies reported a diagnosis of GDM using the 2010 International Association of the Diabetes and Pregnancy Study Groups criteria,\(^5^0\) which was later adopted by the World Health Organization in 2013\(^5^1\); around a fifth of studies used the Carpenter and Coustan criteria,\(^5^2\) and around a quarter of included studies did not report on the diagnosis criteria, or used criteria from within their own institution.

3.3 | Narrative review and meta-analysis

Supporting Information (Figures S1–S7) illustrates the narrative results reporting on mean differences in each metabolic factor between women with and without GDM. Figures 2–10 present the OR (95% CI)
| Author, country | Type of study | Study population and sample size | Years | Inclusion criteria | Exclusion criteria | GDM diagnosis and time point | Main exposure in model (e.g., BMI, TG) | Adjustments made |
|----------------|--------------|----------------------------------|-------|-------------------|-------------------|-----------------------------|--------------------------------------|----------------|
| Madhavan 2008, India | Prospective cohort | Outpatients of Ob/Gyn Department, Government Medical College Hospital, Kottayam, Kerala. Enrolled during first antenatal visit n = 106; GDM n = 8 | April 2005–April 2006 | Single live intrauterine pregnancies; gestational age ≤12 weeks' gestation; maternal age 18–35 years | History of diabetes pre-pregnancy, history of drugs known to cause insulin resistance within prior 6 months; history of thyroid or pituitary disorders; comorbid conditions and severe systemic illness | World Health Organization (WHO) 1999 criteria, at 24–28 weeks' gestation. | BMI, waist circumference (WC), waist hip ratio (WHR) and fasting blood sugar | Not reported |
| Cozzolino 2017, Italy | Single centre retrospective cohort study | n = 656 January 2010–January 2016 | All multiple pregnancies screened for GDM with 75 g, 2 h OGGT at 24–28 weeks' gestation | Maternal pre-gestational diabetes and hypertension or other chronic diseases (i.e., cardiovascular, autoimmune diseases, inherited and acquired thrombophilia); absence of the 75 g OGGT screening during pregnancy; major foetal congenital anomalies; twin-to-twin transfusion syndrome; miscarriage or intrauterine foetal death before the OGGT | International Association of Diabetes and Pregnancy Study Groups criteria (IADPSG), at 24–28 weeks’ gestation. | BMI | Not reported |
| Hinkle 2018, USA | Nested case control study | Enrolled between 8 and 13 weeks' gestation; n = 2802; GDM n = 107, matched non-GDM controls n = 214 | 2009–2013 | Low-risk, pregnancies among non-obese women and 468 pregnancies among obese women (n = 2802 total). The inclusion criteria for obese cohort included women | Non-obese women who smoked, had GDM in a prior pregnancy or had a haematologic disorder (e.g., chronic anaemia, sickle cell disease, low platelets, blood clotting problems) were excluded; as were Carpenter and Coustan criteria, as endorsed by the American Diabetes Association (ADA), and the American College of Obstetrics and Gynaecologists | HbA1c | Maternal age, gestational age at delivery, family history of diabetes, pre-pregnancy overweight and obesity |

(Continues)
| Author, country | Type of study | Study population and sample size | Years | Inclusion criteria | Exclusion criteria | GDM diagnosis and time point | Main exposure in model (e.g., BMI, TG) | Adjustments made |
|----------------|--------------|----------------------------------|-------|-------------------|-------------------|-----------------|---------------------------------|----------------|
| Zhu 2020, China | Prospective cohort | n = 2949; GDM n = 581 (19.7%) | July 2016–June 2017 | Between 6 and 8 weeks' gestation; aged >18 years; singleton pregnancy; regular prenatal visits; opted to deliver at Fu Xing Hospital | women with HbA1c ≥ 6.5% (48 mmol/mol) at enrolment (n = 3) or who had a haemoglobin variant (n = 6). | (ACOG), at 24–29 weeks' gestation. | Fasting (>8 h) triglycerides (TG) at 6–8 weeks' gestation; stratified for pre-pregnancy BMI | Maternal age, fasting blood glucose, pre-pregnancy BMI, family history of DM |
| Godwin 1999, Canada | Retrospective cohort | n = 1298; GDM n = 110 (8.5%) | 1 January 1987–31 December 1995 | Swampy Cree women who gave birth at Weeneebayko Hospital, Moose Factory, James Bay, Ont. | Women who were transferred to other hospitals (n = 30). Large amounts of data missing | International Workshop-Conference on Gestational Diabetes; or fasting sugar or a 1-h 50-g challenge test was done, resulting in a blood glucose value of 7.8 mmol/L. | Waist circumference, weight at first visit | Age, history of GDM in a previous pregnancy, diastolic blood pressure, weight at first prenatal visit, first degree relative with GDM |
| Grieger 2018, Australia and New Zealand | Prospective cohort | n = 3126 (55.6% of total population); GDM = 14.7% | November 2004 – November 2011 | Low-risk, nulliparous women, at 14–16 weeks' gestation with singleton pregnancies recruited from Adelaide | High risk for various pregnancy complications, including preeclampsia, small for gestational age or spontaneous preterm birth; took high dose | WHO 2013 criteria, at 24–28 weeks' gestation. | Waist circumference (WC), TG, HDL-C, sBP, dBP, glucose, MetS | Maternal BMI, age, study centre, SEI, ethnicity, foetal sex, physical activity, smoking status, depression status |
| Author, country | Type of study | Study population and sample size | Years | Inclusion criteria | Exclusion criteria | GDM diagnosis and time point | Main exposure in model (e.g., BMI, TG) | Adjustments made |
|----------------|---------------|---------------------------------|-------|-------------------|-------------------|-----------------------------|----------------------------------------|------------------|
| Doi 2020, UK   | Retrospective cohort | $n = 132,899; \text{GDM} n = 1877 (1.42\%)$ | January 2007 – December 2015 | All women within the Scottish Morbidity Record 01 or 02 or Scottish Birth Record with first time singleton deliveries. | Mothers aged below 20 years and over 40 years were excluded (post hoc) | WHO’s International Classification of Diseases, Tenth revision (ICD-10). | BMI | Maternal age at delivery, smoking during pregnancy, Carstairs 2001 quintiles for socioeconomic status in Scotland |
| Yachi 2011, Japan | Prospective cohort | Pregnant women who visited the obstetrics clinic in Tokyo <13 weeks' gestation, $n = 509$ | September 2008 – January 2010 | Pregnant women who visited the obstetrics clinic in Tokyo <13 weeks' gestation and without recognised diabetes prior to pregnancy | Fasting plasma glucose (FPG) levels <2.5 mmol/l ($n = 3$). Missing or incomplete blood glucose data ($n = 15$). | Japan Society of Obstetrics and Gynaecology criteria, at 24 – 29 weeks' gestation. | BMI, FPG | Maternal age, parity, BMI at first prenatal visit, gestational weight gained per week up to GCT. |
| Iyoke 2013, Nigeria | Nested case control study within a retrospective cohort | All booked parturient women who delivered at three major maternity centres; $n = 648$; early pregnancy obesity $n = 324$; control (normal weight) $n = 324$ | 1 January 2010–31 December 2011 | Cases: Parturient women with BMI $\geq 30$ kg/m$^2$ Controls: Parturient women who booked in the first trimester with normal BMI and matched with cases in age and parity. | $n = 16$ obese women refused to be included in the study. Only included obese women and matched controls. | Not reported | BMI | Not reported |
| Schrauwers 2009, Australia | Retrospective cohort | Singleton pregnancies at the Lyell McEwin Hospital, South | January 2006 – June 2006 | Singleton pregnancies delivered at Lyell McEwin Hospital, | Case records; no other data reported. | BMI | Not reported | (Continues) |
| Author, country | Type of study | Study population and sample size | Years | Inclusion criteria | Exclusion criteria | GDM diagnosis and time point | Main exposure in model (e.g., BMI, TG) | Adjustments made |
|-----------------|---------------|---------------------------------|-------|-------------------|-------------------|----------------------------|--------------------------------------|-----------------|
| Australia       |               | Adelaide with complete medical records. |       |                   |                   |                           |                                       |                 |
| Migda 2016, Poland | Prospective observational | Cases: Caucasian women in singleton pregnancies \(n = 124\) between 11 and 13 weeks' gestation with metabolic syndrome (MetS). Controls \(n = 30\): Healthy pregnant women GDM, \(n = 19\) | 2011–2013 | Single, live pregnancy and 3 of 5 risk factors: Population-specific elevated WC; drug treatment for elevated TG or elevated blood pressure or elevated fasting glucose; reduced high density lipoprotein cholesterol (HDL-C) <40 mg/dl (1.0 mmol/L) in males and <50 mg/dl (1.3 mmol/L) in females. Controls: 30 women with healthy pregnancies. | Not specified but they included 124 cases from the total of 127 cases. | Polish Gynaecology Society criteria, at 24–28 weeks' gestation MetS | Fasting blood sugar, blood pressure | Age and BMI, family history of diabetes, and gravidity |
| Kouhkan 2018, Iran | Nested case-control | Singleton pregnancies \(n = 270\); GDM \(n = 135\), controls \(n = 135\) | October 2016–June 2017 | ART singleton pregnancy, aged 20–40 years | Pre-existing diabetes; multiple pregnancy and chronic diseases such as hypertension, cardiovascular diseases, untreated thyroid disease, liver diseases, renal diseases, autoimmune diseases, and connective tissue disorders; those taking corticosteroids | ADA/IAPDSG criteria, at 24–28 weeks' gestation | Age and BMI, family history of diabetes, and gravidity |
| Phaloprakarn 2009 | Retrospective cohort | Cohort 1 \(n = 1876\); GDM \(n = 586\) Cohort 1 March 2005- | Both cohorts; singleton | Not reported | Carpenter and Coustan criteria, | BMI | Age, parity, family history of |
TABLE 1 (Continued)

| Author, country | Type of study | Study population and sample size | Years | Inclusion criteria | Exclusion criteria | GDM diagnosis and time point | Main exposure in model (e.g., BMI, TG) | Adjustments made |
|-----------------|---------------|----------------------------------|-------|-------------------|-------------------|-----------------------------|---------------------------------------|-----------------|
| Thailand        | Cohort 2      | (31.2%) Cohort 2 (validation cohort) n = 1900; GDM n = 469 (24.7%) | October 2006. Cohort 2 July 2007–December 2005 | pregnancy, no overt diabetes, certain last menstrual period (LMP), first trimester (14 weeks’ gestation) | at 24–28 weeks’ gestation | diabetes, prior macrosomia, history of ≥2 abortions |
| Sweeting 2017, Australia | Retrospective case control | n = 978; GDM n = 248, non-GDM n = 730 | April 2011–May 2013 | Singleton pregnancy; attending Royal Prince Alfred Hospital, Sydney; at 11–13 + 6 weeks’ gestation | Pre-existing diabetes; pre-eclampsia; multiple pregnancies; pre-term delivery (<37 weeks’ gestation); miscarriage; stillbirth; termination; foetal chromosomal abnormality; missing clinical data; where GDM was diagnosed based on a glucose challenge test alone | Australasian Diabetes in Pregnancy (ADIPS) diagnostic criteria, at 24–28 weeks’ gestation | BMI | Previous GDM, family history of diabetes, age, south/east Asian ethnicity, parity. |
| Gur 2014, Turkey | Prospective cohort | n = 106; included n = 94 | January 2012–January 2013 | Maternal age 18–40 years; singleton 4–14 weeks’ gestation | Pregnant subjects with type 1 or 2 diabetes; hypertension; any additional metabolic disease; on chronic drug therapy; newly diagnosed type 2 diabetes based on GCT and OGTT during the study (n = 6); lost to follow up (n = 6) | National Diabetes Group criteria, at 24 weeks’ gestation. | WC, BMI, BP, glucose, total cholesterol (TC), TG, HDL, LDL, insulin, homeostasis model assessment-insulin resistance index (HOMA-IR) | Maximum pre-peritoneal visceral fat, minimum subcutaneous fat and BMI |
| Lei 2016, China | Prospective cohort | n = 5535; GDM n = 1138 (20.56%) | January 2012–December 2014 | If they attended before 20 weeks’ gestation (mean 16 weeks) | Multiple pregnancy, conception by means of gonadotropin ovulation induction or in vitro fertilisation, ischaemic heart disease, stroke, | IADPSG criteria, at 24–28 weeks’ gestation. | BMI, fasting plasma glucose, HDL-C and TG, blood pressure | Maternal age and parity |

(Continues)
| Author, country | Type of study | Study population and sample size | Years | Inclusion criteria | Exclusion criteria | GDM diagnosis and time point | Main exposure in model (e.g., BMI, TG) | Adjustments made |
|----------------|---------------|---------------------------------|-------|-------------------|-------------------|-----------------------------|------------------------------------|-----------------|
| Zhu 2019, USA | Prospective cohort study followed by a nested case-control | $n = 1839$; Screened GDM $n = 1759$; final cohort sample $n = 1750$, GDM $n = 186$ (10.6%) nested case-control study: GDM $n = 116$, matched controls $n = 230$ | Preganancies delivered as of August 2016 | Multi-racial/ethnic pregnant women, aged 18–45 years, <11 weeks’ gestation | Multiple gestations, pre-existing diabetes, cancer, hepatitis C, liver cirrhosis, pregnancy termination, diagnosis of diabetes/use of diabetes medication before baseline examination, missing WC or HC data ($n = 9$) | Carpenter and Coustan criteria, at 24–28 weeks’ gestation | BMI, WC | Risk estimates were adjusted for gestational age at waist and hip circumference measurement |
| Zhu 2013, China | Prospective | $n = 17,186$; GDM $n = 3002$ (17.5%) | January 1 – 29 February 2012 | All women registered to clinic during those times whose blood glucose test results were linked to gestational week. | Pre-existing diabetes | Criteria established by Ministry of Health China. Diagnosis with meeting or exceeded 75 g OGTT: 0 h (fasting), 5.10 mmol/L; 1 h, 10.00 mmol/L; and 2 h, 8.50 mmol/L. 24–28 weeks’ gestation | Not reported |
| Zhang 2019, China | Prospective observational | $n = 1704$; GDM $n = 544$ (37.2%) | March 2017 – September 2017 | Healthy women; natural conception; singleton pregnancy; gestational age 8–12 weeks’ gestation | Type 1 and 2 diabetes prior to pregnancy; fasting plasma glucose >7 in 1st trimester; cardiovascular diseases; inherited metabolic diseases or thyroid diseases | IADPSG criteria, at 24–28 weeks’ gestation | TG, HDL-C (also TC and LDL-C) | Maternal age, pre-pregnancy BMI, gravidity, parity, history of GDM, family history of DM, maternal education, family income, exercise habits pre-pregnancy, |
| Author, country | Type of study       | Study population and sample size | Years          | Inclusion criteria                                                                 | Exclusion criteria                                      | GDM diagnosis and time point | Main exposure in model (e.g., BMI, TG) | Adjustments made                                                                                                                                 |
|----------------|---------------------|---------------------------------|----------------|---------------------------------------------------------------------------------|----------------------------------------------------------|-------------------------------|--------------------------------------|-----------------------------------------------------------------------------------------|
| Magann 2013, Australia | Retrospective cohort study | $n = 4490; \text{GDM BMI} < 25 \text{ kg/m}^2, n = 2.8\%$ | January 2007–July 2008 | Initial antenatal visit in 1st trimester; singleton pregnancies >20 weeks’ gestation | Not reported                                              | Not reported | BMI | Maternal age, nulliparity, ethnicity, pre-existing diabetes, pre-existing hypertension, pregnancy weight gain |
| Zhao 2014, China | Retrospective cohort study | $n = 411; \text{GDM n} = 52 (12.7\%)$ | 2010–2011 | Not reported | Not reported | Not reported | BMI, TG | Maternal age |
| Simko 2019, Slovakia | Retrospective cohort study | $n = 7122; \text{maternal underweight n} = 741 (10.4\%), \text{normal weight n} = 5400 (76.0\%), \text{overweight n} = 602 (8.5\%), \text{obese n} = 358 (5.0\%)$ | 1 January 2013–31 December 2015 | Singleton deliveries >37 weeks’ gestation | Pregnancies with chronic hypertension; foetal anomalies; type 1 and 2 diabetes | 50 g OGTT at 24–28 weeks’ gestation; Fasting and 2 h post 75 g OGTT values were >5.5 mmol/l and >8 mmol/l, respectively. No other criteria/guideline reported. | BMI | Maternal age, gestational age, gestational weight gain, smoking |
| O’Malley 2020, Ireland | Prospective observational cohort study | Women with at least one maternal risk factor for GDM $n = 202; \text{GDM n} = 108 (53.5\%)$ | October 2017–November 2018 | Maternal age ≥18 years; understood English; ≥1 maternal risk factor for GDM | Multiple pregnancy; pre-existing diabetes mellitus. | WHO 2013 criteria, at 26–28 weeks’ gestation. | Obesity (no BMI reported), TG, HDL-C (non-MetS = TC, LDL-C, TG:HDL-C ratio) | Pre-pregnancy BMI |
| Wang 2016, China | Retrospective cohort study | $n = 5218; \text{GDM n} = 1053 (20.2\%)$ | 20th June–30th November 2013 | Live-born singleton infant; full information on early pregnancy lipid profiles (14 weeks’ gestation); | Pre-existing diabetes; hypertension; thyroid disease or immune system disorders; multiple births; missing data on major items such as pre-75 g OGTT >24 weeks’ gestation. Diagnosis of GDM made when any one value met or exceeded the | TG, HDL-C (also TC and LDL-C) | Maternal age, pre-pregnancy BMI, gravidity, parity, education, family history of diabetes, gestational age at |

(Continues)
| Author, country | Type of study | Study population and sample size | Years | Inclusion criteria | Exclusion criteria | GDM diagnosis and time point | Main exposure in model (e.g., BMI, TG) | Adjustments made |
|----------------|---------------|----------------------------------|-------|-------------------|-------------------|-------------------------------|-------------------------------------|-----------------|
| El-Gilany 2010, Saudi Arabia | Prospective cohort | n = 787; GDM n = 30 (3.8%) | 2007 | All women attending PHCCs for antenatal care within the first month of pregnancy and willing to come for regular follow-up throughout pregnancy | Any pre-pregnancy chronic medical disease (e.g., hypertension, diabetes, renal or cardiac disease, sickle cell disease), multiple pregnancies | Not reported | BMI | Not reported |
| Wen-Yuan 2016, China | Prospective population-based cohort | Chinese women pregnant at 28–37 weeks’ gestation; n = 934; GDM n = 71 (7.6%) | June 2010–June 2011 | Pregnant at 28–37 weeks’ gestation; integrated medical records and clear gestational age; singleton pregnancy; naturally conceived | Multiple pregnancy; diabetes; chromosomal abnormalities; inherited metabolic diseases or thyroid diseases before pregnancy; experienced serious infection during early pregnancy; conceived with assisted reproductive techniques | IADPSG criteria, at 24–28 weeks’ gestation | Fasting bloods taken at 7–10 weeks’ gestation for TC, TG, HDL-C and LDL-C concentrations, maternal pre-pregnancy BMI (WHO categories [41]) | Maternal age, pre-pregnancy BMI, gestational weight gain, parity, maternal education, socioeconomic status, infant sex and delivery mode, family income, smoking |
| Denison 2014, UK | Retrospective population-based cohort | <16 weeks’ gestation recruited n = 109,592 (124,280 deliveries); GDM n = 503 (4.4%). | January 2003–February 2010 | Maternal BMI recorded <16 weeks’ gestation; weight 35–140 kg | >140 kg, >44 weeks’ gestation, birth weight >6 kg, BMI assessed >16 weeks’ gestation | Scottish morbidity records 2 (SMR02) held at ISD of NHS Scotland. No time point recorded. | Maternal BMI <16 weeks’ gestation, grouped according to WHO BMI categories (41). | Maternal age, smoking, Carstrairs quintile |
| Author, country | Type of study | Study population and sample size | Years | Inclusion criteria | Exclusion criteria | GDM diagnosis and time point | Main exposure in model (e.g., BMI, TG) | Adjustments made |
|----------------|---------------|----------------------------------|-------|-------------------|-------------------|-----------------------------|---------------------------------------|-----------------|
| Han 2018, China | Prospective population-based cohort | n = 17,803; GDM n = 1383 (7.8%) | October 2010–August 2012 | Women registered with primary care hospital at <12 weeks; non-fasting 50 g 1 h GCT at 24–28 weeks’ gestation | Did not undergo GCT; positive GCT but did not undergo formal OGTT; had pre-existing diabetes | IADPSG criteria, at 24–28 weeks’ gestation. | BMI, WC | Maternal age, height, family history of DM in 1st degree relatives, GA at registration, parity ≥1, education >12 years, Han nationality, non singleton pregnancy, SBP at registration, weight gain per week from registration to GCT, smoking and drinking status before pregnancy. |
| Pazhohan 2019, Iran | Prospective | 24–29 years; 48.5% of study cohort was overweight or obese. n = 954; control n = 778, GDM n = 176 | August 2014–February 2016 | Singleton pregnancy at 1st trimester; attended health centres for first prenatal visit and invited to participate in the study; blood sampling at 9 weeks’ gestation | Type 1 or 2 diabetes pre-pregnancy; FPG ≥126 mg/dl in the first trimester of current pregnancy; cardiovascular diseases; maternal age 18–35 years | IADPSG criteria, at 24–28 weeks’ gestation. | FPG, TC, HDL-C, LDL-C, TG, HDL/LDL ratio, TyG index (TG glucose index) | Age, family history of diabetes, 1st trimester BMI |
| Syngelaki 2011, UK | Prospective | Singleton pregnancies at 11–13 weeks’ gestation n = 45,191; included n = 41,577 | Not reported | Singleton pregnancies with live foetus and crown rump length of 45–84 mm at 11–13 weeks’ gestation, complete data. | Pregnancies conceived by intrauterine insemination incomplete data on pregnancy outcome, pre-pregnancy type 1 or 2 diabetes, ending in miscarriage or delivery <30 weeks (no screening and diagnosis of GDM) | WHO criteria, 2006 at 24–28 weeks’ gestation. | BMI | Maternal age, racial origin, method of conception, cigarette smoking during pregnancy, history of chronic hypertension, history of type 1 or 2 diabetes mellitus (DM), and obstetric |
| Author, country | Type of study | Study population and sample size | Years | Inclusion criteria | Exclusion criteria | GDM diagnosis and time point | Main exposure in model (e.g., BMI, TG) | Adjustments made |
|----------------|---------------|---------------------------------|-------|-------------------|-------------------|-----------------------------|---------------------------------|-----------------|
| Sánchez-Vera 2007, Spain | Prospective nested case-control | n = 107; GDM n = 62, non-GDM n = 45 | July 2001–July 2004 | All women attending obstetric clinic asked to participate; only white women who spoke Spanish fluently included; blood tests performed during routine visits at 15, 24 and 32 weeks | Immigrant women not fluent in Spanish; type 1 and 2 diabetes; multiple pregnancy | American Diabetes Association (ADA), at 24 weeks’ gestation | Glucose, TC, TG, weight, BMI | Plasma levels of cholesterol, TG, vitamin E, oestradiol, progesterone, obesity, time of gestation |
| Falcone 2019, Austria | Prospective cohort | n = 574; GDM n = 103, non-GDM = 471 | January 2016–July 2017 | Not reported | Pre-existing diabetes | IADPSG criteria at the late second or early third trimester (exact gestational week not reported) | Fasting HbA1c, plasma glucose, insulin, C-peptide | Age and BMI |
| Sesmilo 2019, Spain | Retrospective analysis | n = 6845; GDM n = 695 (10.2%) | 2008–2018 | Patients with an available FPG in 1st trimester performed in the laboratory under standard conditions, result <110 mg/dl, patients who had complete data for all outcomes | Patients <18 years, pregestational diabetes, multiple pregnancies and/or pregnancies by means of in vitro fertilisation or gonadotropin ovulation induction | NDDG criteria, in 2nd trimester. | FPG | Multivariate logistic model adjusted by maternal age, BMI at the first antenatal visit, previous pregnancies, gestational age, weight gained in pregnancy (transformed into Z-score) and tobacco use was fitted. |
| Amylidi 2016, Switzerland | Observational retrospective cohort | n = 208; GDM n = 32 (15.2%) | June 2011–November 2012 | Pregnant women attending antenatal clinic with at least one of: BMI ≥ 30 kg/m². | Women with pre-existing diabetes or a first-trimester HbA1c ≥ 6.5% (≥48 mmol/mol) | ADA at 24–28 weeks’ gestation. | HbA1c, BMI | Not reported |
| Author, country | Type of study | Study population and sample size | Years | Inclusion criteria | Exclusion criteria | GDM diagnosis and time point | Main exposure in model (e.g., BMI, TG) | Adjustments made |
|----------------|--------------|---------------------------------|-------|-------------------|-------------------|-----------------------------|-------------------------------------|-----------------|
| Vellamkondu 2017, India | Prospective observational | Women booked between 11 and 14 weeks \( n = 440 \); GDM \( n = 38 \) | Over 2 years (not stated) | Pregnant women booked between 11 and 14 weeks, singleton viable pregnancy, chose to undergo combined screening for aneuploidy (including nuchal translucency and serum biochemistry) | Not reported | Not reported | BMI | Not reported |
| Wang 2013, China | Prospective | \( n = 738 \); PCOS \( n = 114 \), controls \( n = 594 \) | January 2010-December 2012 | Women diagnosed with PCOS \( (n = 220) \) and a matching control group \( (n = 652) \); pregnancy confirmed by transvaginal ultrasonography between 6 and 8 weeks’ gestation | >40 years, pre-existing diabetes, cardiomyopathy accompanied by cardiac insufficiency, active hepatitis, uncontrolled hyperthyroidism, active systemic lupus erythematosus, serious hematopathy, malignant tumours, serious trauma, smoking, drug/alcohol use, organic pelvic disease, pregnancy | At least two values ≥: fasting glucose 5.1 mmol/L, 1 h level 10.0 mmol/L and 2 h level 8.5 mmol/L. 24–28 weeks’ gestation | Incidence of pregnancy outcomes according to conception methods (spontaneous conception, IVF-ET, or ovarian stimulation), age at conception (≤30 years or >30 years), BMI \( (<24 \text{ kg/m}^2 \text{ (lean)} \text{ or } \geq 24 \text{ kg/m}^2 \text{ (overweight/}) \), (Continues)
| Author, country | Type of study | Study population and sample size | Years | Inclusion criteria | Exclusion criteria | GDM diagnosis and time point | Main exposure in model (e.g., BMI, TG) | Adjustments made |
|----------------|--------------|----------------------------------|-------|-------------------|-------------------|-----------------------------|--------------------------------|----------------|
| Knight-Agarwal, Australia 2016 | Retrospective cohort | Women from a Birthing Outcome System database, 1st antenatal visit ~12 weeks’ gestation; n = 14,857 | January 2008–December 2013 | Not reported | Women with missing BMI data and multiple pregnancies were excluded | International Classification of Diseases (ICD)-10 codes and standard operating procedures developed by the tertiary institution where the study was conducted. | BMI, glucose tolerance state (NGT or GDM) |
| Collier, UK 2017 | Retrospective cohort | Data extracted from the Scottish Morbidity Record 02, >31 years; n = 1,891,097; included in analysis (from 2012 subgroup); n = 47,290 | 1 January 1981–31 December 2012 | Not reported | Delivering at home or in non-NHS hospitals | Coded as GDM or if any of the diagnosis were coded as O244 (ICD10) or 6488 (ICD9) in the SMR02 dataset. | BMI, maternal age, parity, country of birth, smoking status |
| Savvidou, UK 2010 | Nested case-control study | First trimester maternal samples from 124 women who developed GDM and 248 control subjects who did not (11 + 0–13 + 6 weeks) | Not stated | Not stated- All women had phenotypically normal neonates. | Women with pre-existing diabetes and twin pregnancies were excluded | 1999 WHO criteria, at 24–28 weeks' gestation | BMI, BP, TC, LDL, HDL, non-fasting TG, maternal age, BMI, gestational age at sampling, smoking, ethnicity, parity, conception status, and previous GDM |
| Kansu-Celik, Turkey 2019 | Retrospective cohort | Women at 1st trimester screening between 6 and 14 weeks’ gestation; n = 608; GDM n = 69, non-GDM | January 2010–January 2018 | HbA1c levels were measured <14 weeks’ gestation | Multiple gestations, clinical evidence or history of any systemic disease or pregestational diabetes (types 1 and 2), hypertension, FPG exceeding 126 mg/dl, Carpenter and Coustan criteria, at 24–28 weeks' gestation. | FPG, HbA1c | Not reported |
| Author, country | Type of study | Study population and sample size | Years | Inclusion criteria | Exclusion criteria | GDM diagnosis and time point | Main exposure in model (e.g., BMI, TG) | Adjustments made |
|----------------|--------------|---------------------------------|-------|-------------------|-------------------|----------------------------|----------------------------------|----------------|
| Farah 2012, Ireland | Prospective observational | $n = 2000; \text{included } n = 1935; \text{GDM screening } n = 547, \text{GDM } n = 70$ | July 2008–March 2010 | White European women; singleton pregnancy | Pre-pregnancy diabetes; maternal age <18 years; unable to give consent | ADA criteria, diagnosed around 28 weeks’ gestation | BMI | Not reported |
| Bao 2018, USA | Nested case-control | $n = 321; \text{GDM } n = 107, \text{non-GDM } n = 214$ | 2009–2013 | 4 race/ethnic groups; maternal age 18–40 years; singleton pregnancy; pre-pregnancy BMI 19–45 kg/m² | HIV: major chronic conditions such as pre-pregnancy hypertension, pre-pregnancy diabetes, cancer, psychiatric, renal or autoimmune diseases | ACOG criteria. Diagnosis time point not reported (but excluded women with GDM <26 weeks’ gestation) | TC, HDL, TG, LDL | Maternal age, gestational age at blood collection, parity, family history of diabetes, pre-pregnancy BMI |
| Odsæter 2015, Norway | Prospective RCT post hoc analyses | $n = 228; \text{dropped out } n = 12, \text{GDM-WHO } n = 55 \text{(24.1%)}, \text{GDM-IADPSG } n = 35 \text{(15.4%)}$ | February 2995–January 2009 | Pregnant women with PCOS, 18–45 years; singleton pregnancy between 5 and 12 weeks’ gestation | ALT >90 IU/l; creatinine >130μmol/l; known alcohol abuse, previous DM, fasting plasma/serum glucose >7.0 mmol/l at inclusion, treatment with glucocorticoids or use of drugs known to interfere with metformin | WHO 1999 criteria, at 24–28 weeks’ gestation. | HbA1c | GDM 1st trimester and GDM throughout pregnancy: HbA1c, age and BMI at inclusion, GDM in previous pregnancy, using metformin at conception/early pregnancy pre-eclampsia: HbA1c, age and BMI at inclusion, using metformin (Continues) |
| Author, country | Type of study | Study population and sample size | Years | Inclusion criteria | Exclusion criteria | GDM diagnosis and time point | Main exposure in model (e.g., BMI, TG) | Adjustments made |
|----------------|--------------|---------------------------------|-------|-------------------|-------------------|---------------------------|----------------------------------------|-----------------|
| Yang 2019, Australia | Retrospective cohort | Singleton deliveries<br>$n = 35,099$ (GDM data $n = 24,161$ (70% retained); GDM $n = 2126$ (8.8%), non-GDM $n = 22,034$ (91.2%))<br>ACT residents, singleton birth, pregnancy duration of between 24 and 43 weeks | 2009–2015 | ACT residents, singleton birth, pregnancy duration of between 24 and 43 weeks | Missing maternal height or weight | Not reported (some self-reported) | 1st antenatal visit BMI | Maternal age, parity, smoking in pregnancy, Aboriginal and TSI status, socio-economic indexes for areas |
| Sreedevi 2012, India | Observational study (unclear if prospective or retrospective) | $n = 250$; GDM $n = 40$, non-GDM $n = 210$ | Not reported | Women who registered between 7 and 10 weeks’ gestation, regular antenatal check-up and complete records of antenatal and intranatal periods | Not reported | Not reported | First trimester BMI | Not reported |
| Author, country       | Type of study          | Study population and sample size                                                                 | Years                  | Inclusion criteria                                                                 | Exclusion criteria                                                                 | GDM diagnosis and time point               | Main exposure in model (e.g., BMI, TG) | Adjustments made                  |
|----------------------|------------------------|--------------------------------------------------------------------------------------------------|------------------------|-------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------|-------------------------------------|--------------------------------------|
| Zheng 2019, China    | Prospective cohort     | Cohort 1: $n = 566$; PCOS $n = 242$, controls $n = 324$                                      | Cohort 1 January 2013–December 2015. | 8–15 weeks’ gestation; singleton pregnancy; maternal age 18–45 years; history of PCOS or age and pre-pregnancy BMI matched controls | Pre-existing disease (diabetes, hypertension, liver, kidney, thyroid or cardiovascular disease) | ADA criteria, at 24–28 weeks’ gestation. | PCOS, normal BMI $< 25$ and overweight/obese BMI $\geq 25$ | Not reported                        |
| Sánchez-García 2020, USA | Prospective observational | $n = 164$; GDM $n = 29$ (17.7%), non-GDM $n = 135$ (82.3%)                                           | November 2017–October 2019 | Maternal age 18–35 years; in 1st trimester of pregnancy (<14 weeks according to last menstrual period) | Maternal age <18 years, taking any medications or had any illness that could impair insulin secretion/action (e.g., prediabetes, types 1 and 2 diabetes, PCOS Rotterdam criteria [53]); multifetal pregnancy; previous GDM or pre-eclampsia | IADPSG criteria, at 24–28 weeks’ gestation. | Triglycerides, BMI                  | BMI, history of T2DM, abortion      |
| Hashemi-Nazari 2020, Iran | Retrospective cohort | $n = 3100$; analysed $n = 1009$; GDM $n = 80$, non-GDM $n = 929$  | 2015–2016 | Pregnant women referred to 10 health centres. A certain number of pregnant women | Not reported | ADA criteria, at 24–28 weeks’ gestation. | BMI | Age, parity, family history of T2DM, abortion |
| Wani 2020, Saudi Arabia | Longitudinal prospective cohort | $n = 498$; GDM $n = 123$ (24.7%)                                             | Not reported | Normal pregnant Saudi women; age 18–35 years; early pregnancy (<15 weeks’ gestation); singleton pregnancy | Known previous multiple pregnancy; history of diabetes or chronic disease for example, renal or liver disease | IADPSG criteria, at 27 weeks’ gestation | WC, fasting glucose, HDL-C, TG, SBP, DBP, MetS | Age, BMI, parity                  |
| Berggren 2017, USA   | Prospective observational | $n = 300$; analysed $n = 250$; GDM $n = 72$, non-GDM $n = 178$                  | June 2012–June 2013 | Maternal age $\geq 16$ years; singleton pregnancy; gestational age | Known type 2 diabetes | Carpenter and Coustan criteria, at 22 0/7 to 33 6/7 weeks of gestation. | HbA1c, SHBG, BMI | HbA1c, SHBG, race, BMI, history of GDM |
| Author, country | Type of study | Study population and sample size | Years | Inclusion criteria | Exclusion criteria | GDM diagnosis and time point | Main exposure in model (e.g., BMI, TG) | Adjustments made |
|----------------|---------------|----------------------------------|-------|-------------------|-------------------|---------------------------|-------------------------------------|-----------------|
| Grewal 2012, India | Prospective observational | Initial Cohort (12 weeks’ gestation) n = 298; GDM n = 24 | July 2006-July 2009 | Non-diabetic women; registered at antenatal clinic <12 weeks’ gestation | History of overt diabetes; impaired fasting glucose or impaired glucose tolerance at initial prenatal visits; history of GDM or preeclampsia; taking medications known to affect BGL and insulin levels | Carpenter and Coustan criteria, at 24-28 weeks’ gestation. | Early pregnancy plasma glucose, insulin, whole body insulin sensitivity, HOMA-IR, QUICKI | Age and BMI |
| Repeat Cohort (24 weeks’ gestation) | | | | | | | |
| Total Cohort n = 298; GDM n = 40 | | | | | | | |
| Ogonowski 2007, Poland | Retrospective analysis | n = 2425; GDM n = 1414, non-GDM control n = 1011 | January 1999-December 2005 | Pregnant women with abnormal OGTT, referred to the Outpatient Clinic for Diabetic Pregnant | Pre-pregnancy diabetes | WHO criteria 1999, at 24-28 weeks’ gestation. | Fasting plasma glucose | Not reported |
| Arbib 2019, Israel | Retrospective cohort | First trimester n = 142; GDM n = 42, non-GDM n = 100 | 1 August 2007-31 December 2014 | Healthy singleton foetus with no known chromosomal or anatomic malformation and known maternal and neonatal short-term pregnancy outcome | Previous diagnosis of type 1 or 2 diabetes, HbA1C ≥ 6.5%, and/ or fasting plasma glucose ≥126 mg/dl; women whose glucose levels had already been tested <24 weeks of pregnancy, or no GDM screening or testing | Carpenter and Coustan criteria, at 24-28 weeks’ gestation | HbA1C | Not reported |
| Teede 2011, Australia | Retrospective cohort | Early pregnancy (12-15 weeks’ gestation) | 2007-June 2008 | All pregnant women (n = 4276) who delivered at | | ADIPS criteria, at 26-28 weeks’ gestation | BMI | Age, increasing BMI, ethnicity, first-degree family |
| Author, country | Type of study | Study population and sample size | Years | Inclusion criteria | Exclusion criteria | GDM diagnosis and time point | Main exposure in model (e.g., BMI, TG) | Adjustments made |
|----------------|--------------|---------------------------------|-------|-------------------|-------------------|-----------------------------|----------------------------------------|------------------|
| Punnose 2020, India | Retrospective cohort | First trimester (13 6/7 weeks) | January 2011-December 2016 | Pregnant women with singleton pregnancies, HbA1c in 1st trimester | Twins, delivery outside the study hospital, HbA1c >6.5%, previous DM, Haemoglobinopathy | IADPSG criteria, at 24-28 weeks' gestation. | HbA1C | Age, BMI, previous GDM, family history, history of DM, multigravidity, Hb, MCV |
| Berggren 2015, USA | Prospective | Women in pre-natal care or seeking a first trimester ultrasound | June 2012-June 2013 | Age ≥16 years; singleton pregnancies at 11 0/7 to 14 6/7 weeks; planned care and delivery at the study site; English language proficiency | No known history of type 2 diabetes mellitus; if GDM screening was performed at an earlier gestational age and GDM was then either diagnosed or treated based on that early screening, or if repeat GDM screening was not performed in the study-specific gestational age window. | Carpenter and Coustan criteria, at 22-34 weeks' gestation. | HbA1C | SHBG, race, BMI, history of GDM |
| Li 2016, China | Prospective | Women with PCOS in first pre-natal visit (<15 weeks' gestation) | 2011-2013 | 18-45 years, diagnosis of PCOS before conception, singleton pregnancy | Pre-existing chronic diseases including diabetes, hypertension, thyroid, kidney or cardiovascular disease, or multiple pregnancies | ADA criteria, at 24-28 weeks' gestation. | BMI, SBP, DBP, TC, TG, HDL-C, FPG, non-HDL-c, SHBG |
| Riskin-Mashiah 2010, Israel | Retrospective | n = 4876; GDM n = 135 (2.8%), non-GDM n = 4741 | June 2001-June 2006 | Singleton pregnancy; 1st trimester BMI; 1st trimester fasting plasma glucose level | Pre-gestational DM; fasting glucose level >105 mg/dl; delivery at <24 weeks' gestation | Carpenter and Coustan criteria, at 24-28 weeks' gestation. | BMI, fasting glucose | Fasting glucose level, BMI, maternal age, parity |

(Continues)
| Author, country | Type of study | Study population and sample size | Years | Inclusion criteria | Exclusion criteria | GDM diagnosis and time point | Main exposure in model (e.g., BMI, TG) | Adjustments made |
|----------------|---------------|----------------------------------|-------|-------------------|-------------------|-----------------------------|---------------------------------|----------------|-------------------|
| Raja 2012, UK  | Retrospective | $n = 27,668; \text{BMI}<30\ \text{kg/m}^2$; $n = 20,735, \text{BMI}>30\ \text{kg/m}^2$; $n = 3897$ | January 2002–December 2007 | Delivering at Northwick Park Hospital, Harrow; delivery date between 1 January 2002 and 31 December 2007 | Lack of data on weight/height | Not reported (hospital database) | BMI | Maternal age, ethnicity, parity, cigarette smoking |
| Gabbay-Benziv 2015, USA | Prospective cohort | $n = 927; \text{GDM} n = 63 (6.8%), \text{non-GDM} n = 861$ | 2007–2010 | Baltimore metropolitan area; singleton intrauterine pregnancy between 11 and 14 weeks' gestation; prenatal care and subsequent GDM screening at study centre | Strong evidence for pre-GDM, and missing outcomes | Carpenter and Coustan criteria, at 24–28 weeks' gestation. | BMI, BP | Maternal age, ethnicity, prior GDM, first trimester BMI, SBP |
| Basraon 2016, USA | Prospective cohort | $n = 2300; \text{GDM} n = 80 (3.5%), \text{non-GDM} n = 2220$ | 2003–2008 | Singleton pregnancy; 9–16 weeks' gestation; nulliparous women; no history of pre-gestational hypertension, proteinuria, diabetes or other medical problems; substance abuse; foetal abnormalities; uterine bleeding; in-vitro fertilisation | No data of WHR and BMI | GDM diagnosis at 26 weeks' gestation as per the guideline of each centre | BMI, WHR, insulin resistance | Maternal age, education, ethnicity, weeks of gestation at enrolment, alcohol, smoking status |
| Alptehkin 2016, Turkey | Prospective observational | $n = 227; \text{GDM} n = 20 (8.8%), \text{non-GDM} n = 207$ | December 2014–May 2015 | Singleton pregnancy; 7–14 weeks' gestation | Previous type:1 or 2 diabetes, with FPG >95 mg/dl, multiple pregnancies, untreated endocrine disturbances, chronic | Carpenter and Coustan criteria, at 24–28 weeks' gestation. | HOMA-IR, BMI | BMI, WHR, parity, weight gain during pregnancy, HOMA-IR |
| Author, country  | Type of study     | Study population and sample size | Years                  | Inclusion criteria                                                                 | Exclusion criteria                                                                 | GDM diagnosis and time point                  | Main exposure in model (e.g., BMI, TG) | Adjustments made                   |
|-----------------|------------------|----------------------------------|------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|---------------------------------------------|--------------------------------------|--------------------------------------|
| Li 2019, China  | Retrospective    | $n = 2112$; GDM $n = 224$ (10.6%), non-GDM $n = 1888$ | January 2016–June 2017 | First prenatal visit during 9–13 + 6 weeks’ gestation; regular prenatal services; delivered in third affiliated hospital of Sun Yat-Sen University, Guangzhou, China | Diagnosed pregestational diabetes                                                  | IADPSG criteria, at 24–28 weeks’ gestation. | FPG                                  | Pre-pregnancy BMI, first-trimester FPG, maternal age, parity |
| Wolfe 1991, USA | Prospective      | $n = 6270$                       | 30 month period, year not reported | Consecutively delivered of infants at Hutzel Hospital; antepartum and intrapartum records were available | Not reported                                                                      | Not reported                                | BMI, maternal weight             | Not reported                        |
| Nanda 2011, UK  | Prospective, case-control | $n = 11,464$; GDM $n = 297$ (2.6%), non-GDM $n = 11,167$ | March 2006–August 2009 | Women who attended first antenatal visit 11–13 weeks’ gestation; singleton pregnancy; delivered phenotypically normal neonate ≥30 weeks’ gestation | Pre-pregnancy type 1 or 2 diabetes; termination, miscarriage or delivery <30 weeks’ | WHO criteria 2006, at 24–28 weeks’ gestation. | BMI                                  | Maternal age, race, family history of diabetes, parity, cigarette smoking, conception |
| Kumru 2016, Turkey | Prospective cohort | $n = 333$; GDM $n = 38$, non-GDM $n = 295$ | January 2011–January 2013 | Provided blood samples at 6–13 ± 6 weeks’ gestation; Multiple pregnancies; obesity (BMI > 30 kg/m²); history of hypertension; type 1/ | Carpenter and Coustan criteria, at 24–28 weeks’ gestation. | BMIs, MAPs, FBG, insulin, HbA1c, HOMA, TC, LDL-C, and TG | Maternal age, 1st trimester BMI, MAP | (Continues)                           |
| Author, country | Type of study | Study population and sample size | Years | Inclusion criteria | Exclusion criteria | GDM diagnosis and time point | Main exposure in model (e.g., BMI, TG) | Adjustments made |
|----------------|--------------|---------------------------------|-------|-------------------|-------------------|---------------------------|-------------------------------------|------------------|
| Hancerliogullari 2020, Turkey | Prospective cohort | n = 525; GDM n = 49 (9%), non-GDM n = 476 (91%) | August 2018–November 2018 | Low-risk pregnant women at 11–14 weeks' gestation. | Maternal age <18 years or >45 years, multiple pregnancies, women with known hypertension, kidney, liver, thyroid gland and other endocrine diseases, those who were diagnosed with pre-diabetes | Carpenter and Coustan criteria, at 24–28 weeks' gestation. | WC, BMI | Not reported |
| Ozgu-Erdinc 2019, Turkey | Retrospective cohort study | n = 439; GDM n = 49 (11.2%) | January 2011–January 2012 | Patients who had received antenatal care during 1st trimester | Multiple gestations, medications that affect insulin and glucose levels, hypertension or concomitant systemic disease, pre-gestational known diabetes (type 1–2) or glucose intolerance and FPG levels ≥126 mg/dl. Four women were excluded as lost to follow-up | ACOG criteria, at 24–28 weeks' gestation. | FPG | FPG, insulin ratio, HOMA-IR, HOMA-b indices, QUICKI |
| Gao 2020, China | Prospective cohort | Training dataset n = 12,887; GDM | October 2010–August 2012 | 19,331 pregnant women registered | History of type 1 or 2 diabetes before | Changed from WHO 1999 criteria to | BMI, SBP, DBP, weight, WC | Not reported |
| Author, country    | Type of study | Study population and sample size | Years | Inclusion criteria | Exclusion criteria | GDM diagnosis and time point | Main exposure in model (e.g., BMI, TG) | Adjustments made |
|-------------------|---------------|----------------------------------|-------|-------------------|-------------------|-----------------------------|----------------------------------------|-----------------|
| Liu 2020, China   | Prospective   | Singleton pregnancy, n = 352; GDM n = 66 (18.8%), non-GDM n = 286 | October 2018–December 2018 | Singleton pregnancy, followed up prospectively from the first prenatal visit until delivery. | Not a singleton pregnancy; not Han ethnicity; fasting glucose ≥6.1 mmol/L and/or HbA1c >6.5% or diagnosed as diabetes before pregnancy; history of autoimmune disease, or currently use corticosteroids; hyperthyroidism or hypothyroidism; miscarried or induced labour before OGTT at 24–28 weeks; history of liver or renal insufficiency or CRP >10 mg/L; suspected familial hypertriglyceridemia; incomplete records of IADPSG/WHO criteria, at 24–28 weeks of gestation. | IADPSG criteria, at 24–28 weeks of gestation. | BMI, TG, HDL-C, TC | Age, education, physical activity, BMI (at enrolment), parity, family history of diabetes, history of PCOS, CRP, labour method, foetal sex, gestation age and weight gain |
| n = 979 (7.6%).   |               | Test dataset n = 6444; GDM n = 506 (7.9%) |       | for antenatal care and two-step GDM screening. Dataset was randomly divided into two using a computer-generated random number: The training dataset and the test dataset, with the ratio of sample size of 2:1. The training dataset was used to develop the risk score and the test dataset was used to validate. | pregnancy, 936 who registered and attended their first antenatal care in more than the 15th gestational week, 1163 women who did not undergo GCT, and 851 women who had a positive GCT but did not undergo OGTT. | IADPSG criteria in 2010, at 24–28 weeks of gestation. | BMI, TG, HDL-C, TC | Age, education, physical activity, BMI (at enrolment), parity, family history of diabetes, history of PCOS, CRP, labour method, foetal sex, gestation age and weight gain |
| Author, country | Type of study | Study population and sample size | Years | Inclusion criteria | Exclusion criteria | GDM diagnosis and time point | Main exposure in model (e.g., BMI, TG) | Adjustments made |
|----------------|--------------|----------------------------------|-------|-------------------|-------------------|----------------------------|-----------------------------------|-----------------|
| Meek 2021, UK  | Retrospective | Older Cambridge University Hospital NHS Foundation Trust cohort, n = 17,736; GDM cases not specified | 2004–2008 | n = 17,736 consecutive women with singleton pregnancies, with random plasma glucose at booking | Not reported | UK National Institute for Health and Care Excellence (NICE; 0 min = 5.6 mmol/l; 120 min = 7.8 mmol/l) and the IADPSG, adopted by the WHO; 0 min = 5.1; 60 min = 10.0; 120 min = 8.5 mmol/L, at 28 weeks’ gestation. | Glucose | Not reported |
| Guo 2020, China | Retrospective cohort was used to develop a prediction model which was assessed on a prospective cohort study | Retrospective cohort, n = 3956; GDM n = 662, non-GDM n = 3294 | January 2015–December 2015 | Eligible subjects who underwent 1st-trimester screening at the International Peace Maternity and Child Care Health Hospital were recruited at 9–13 weeks' gestation | Pre-existing diabetes mellitus (FPG ≥7 mmol/L or HbA1c ≥ 6.5% during the first antenatal care or self-reported previous diabetes), multifetal pregnancies, missing data | ADA criteria, at 24–28 weeks’ gestation. | FPG, HbA1c | Advanced age, high pre-pregnancy BMI, diabetes in first degree relatives |
| Wang 2016, China | Retrospective cohort | n = 15,194; included n = 5265; GDM n = 1062, non-GDM n = 4203 | 20 June 2013–30 November 2013 | Singleton pregnancies delivered between 20 June 2013, and 30 November 2013; Pre-existing diabetes mellitus (n = 209), multiple births (n = 253), missing data on early pregnancy lipid and fasting glucose concentrations (n = 9467). | China recommendations: When any one value met or exceeded a 0 h glucose level of 5.1 mM, a 1 h glucose level of 10.0 mM, and a 2 h glucose level | Fasting glucose, TC, TG | Age, family history of DM |
| Author, country | Type of study | Study population and sample size | Years | Inclusion criteria | Exclusion criteria | GDM diagnosis and time point | Main exposure in model (e.g., BMI, TG) | Adjustments made |
|----------------|---------------|---------------------------------|-------|-------------------|-------------------|----------------------------|----------------------------------------|-----------------|
| Al-Shafei 2021, Sudan | Nested case-control | GDM: 60, non-GDM:60 | January–November 2017 | Singleton pregnancies who attended the prenatal care clinic of the hospital during early pregnancy (≤14 weeks’ gestation). | Pregnant women with any chronic disease (e.g., diabetes or history of GDM, hypertension, renal disease, liver disease, or thyroid disease) and women who were on medication were excluded | IADPSG, at 24–28 weeks’ gestation | FBG, BMI | Not reported |
| Zhang 2020, China | Prospective cohort | GDM: 274, non-GDM:1111 | December 2017–March 2019 | Recruited at 7–12 weeks’ gestation | Not reported | IADPSG criteria, at 24–28 weeks’ gestation | FBG, HbA1c, HDL-C, SBP, DBP, TG, BMI | Age, BMI, and parity |
| Tenenbaum-Gavish 2020, Israel | Prospective cohort | GDM:20; non-GDM:185 | October 2014 and March 2016 | Singleton viable gestation when undergoing combined first trimester screening for aneuploidy. Patients with placenta support hormonal treatment for in vitro fertilization were only included after discontinuing treatment. | Foetal aneuploidies or major foetal anomalies, increased nuchal translucency thickness >3.5 mm or treatment with aspirin prior to enrolment; termination, miscarriage, or foetal death before 24 weeks’ gestation, pre-eclampsia, birthweight <5th percentile for gestational age, delivered <37 weeks’ gestation | Carpenter and Costan criteria, at 24–28 weeks’ gestation. | BMI, SBP, DBP | Not reported |
| Leng 2015, China | Prospective cohort | GDM: 1378; non-GDM: 16,430; within 12 weeks of gestation | October 2010–August 2012 | Not reported | Women who did not have GCT at 24–28 weeks’ gestation | 1999 WHO criteria, at 24–28 weeks’ gestation. | BMI, SBP, DBP | Age, BMI, and parity, Han nationality, SBP, family history of (Continues) |
| Author, country          | Type of study | Study population and sample size | Years           | Inclusion criteria | Exclusion criteria | GDM diagnosis and time point | Main exposure in model (e.g., BMI, TG) | Adjustments made                                                                 |
|-------------------------|---------------|----------------------------------|-----------------|-------------------|-------------------|-----------------------------|--------------------------------------|--------------------------------------------------------------------------------------|
| Schneider 2021,         | Prospective   | GDM: 184; non-GDM: 974           | March 2015–December 2017 | Not reported      | Not reported      | WHO 2013 criteria, classification, at 24–28 weeks’ gestation. | MetS                                  | diabetes in first degree family, education, weight gain from pre-pregnancy to GCT, smoking and drinking habits |

**Note:** Criteria used for GDM diagnoses:

- **WHO 1999:** Fasting glucose ≥7.0 mmol/L (126 mg/dl); ≥7.8 mmol/L (140.4 mg/dl) for 2-h plasma glucose.
- **IADPSG, 2010/WHO 2013:** Fasting plasma glucose = 5.1–6.9 mmol/L (92–125 mg/dl); 75 g oral glucose load: 1-h ≥10.0 mmol/L (180 mg/dl), 2-h 8.5–11.0 mmol/L (153–199 mg/dl).
- **Carpenter-Coustan/ADA:** 100 g oral glucose load: Fasting, 95 mg/dl (5.3 mmol/L), 1-h, 180 mg/dl (10.0 mmol/L), 2 h, 155 mg/dl (8.6 mmol/L), and 3 h, 140 mg/dl (7.8 mmol/L).
- **Australasian Diabetes in Pregnancy:** Fasting blood glucose level (BGL) ≥5.5 mmol/L (100 mg/dl) and/or 1-h BGL ≥10.5 mmol/L (190 mg/dl) and/or 2-h BGL ≥8.0 mmol/L (144 mg/dl); or a screening 50 g glucose challenge test (GCT) and if positive (1-h BGL ≥7.8 mmol/L [140 mg/dl]), a subsequent OGTT.
- **American College of Obstetrics and Gynaecologists:** Fasting plasma glucose: ≥5.3 mmol/L; 100 g OGTT: 1-h plasma glucose ≥10.0 mmol/L and 2-h plasma glucose ≥8.6 mmol/L.
- **National Diabetes Group:** Fasting, 1-h, 2-h, and 3-h plasma glucose levels of 105 mg/dl (5.8 mmol/l), 190 mg/dl (10.5 mmol/L), 165 mg/dl (9.2 mmol/L), and 145 mg/dl (8.0 mmol/L).
of maternal prognostic metabolic factors in early pregnancy and the likelihood for GDM. The results of the individual factors are summarised below.

3.3.1 Waist circumference (WC)

Six cohort studies assessed WC with sample sizes ranging from 247 to 19,186. Overall, women who developed GDM had a larger WC measured in early pregnancy, with a mean difference of 6.20 cm compared to women without GDM (p < 0.0001; Supplementary Figure S1). Studies were not pooled in the meta-analysis as they did not report on OR or RR.

3.3.2 Body mass index (BMI)

Body mass index was derived from recorded medical history data, self-report, or from a measurement at the first antenatal visit. There were 44 cohort and six nested case-control studies, with sample sizes ranging from 106 to 132,899 participants. Overall, the mean BMI was 2.28 kg/m² higher in women with GDM compared to women without GDM (p < 0.00001; Supplementary Figure S2).

Seven cohort and five case-control studies with continuous BMI data were included in meta-analyses. For every unit increase in BMI, there was a slight increase in odds for GDM in unadjusted analysis (OR 1.08, 95% CI 1.03–1.13, k = 6; Figure 2A) and analyses adjusted for age, as a key criterion, and up to another 10 confounders (aOR 1.11, 95% CI 1.07–1.14, k = 5; Figure 2B). There was clear heterogeneity across the studies (I² ≥ 87%, Phet < 0.00001 for both).

Fourteen studies reported on an overweight BMI (>25–<30 kg/m²), demonstrating a 2-3 fold increased odds for GDM in unadjusted analyses (OR 2.75; 95% CI 2.02–3.74, k = 6; Figure 3A) and analyses adjusted for age, and up to four other confounders (OR 2.17; 95% CI 1.89–2.50, k = 12; Figure 3B). There was high statistical heterogeneity (I² ≥ 73%, Phet ≤ 0.002 for both). For the 13 studies including women with obesity (BMI > 30 kg/m²), an obese BMI was associated with a 4-fold increased odds of GDM unadjusted OR 4.45; 95% CI 2.77–7.15, k = 8, Figure 4A; adjusted OR 4.34; 95% CI 2.79–6.74, k = 9, Figure 4B), with high statistical heterogeneity (I² ≥ 90%, Phet < 0.00001 for both).

3.3.3 Blood pressure

Ten cohort and two case-control studies provided data on systolic (SBP), diastolic (DBP), and mean arterial blood pressure with sample sizes ranging from 205 to 17,808 participants.

Women with GDM had 3.15 mmHg higher mean SBP (p < 0.0001;
Supplementary File 2)\(^{33,58,64,66,99–102}\) and 1.78 mmHg higher mean DBP (\(p < 0.0001\); Supplementary Figure S3)\(^{33,58,64,66,99–102}\) compared to women without GDM.

Raised blood pressure (SBP > 130 mmHg or DBP > 85 mmHg)\(^{24,53}\) or raised SBP\(^{76,106}\) was associated with increased odds for GDM (OR 2.25 95% CI 1.34–3.81, \(k = 2\), adjusted for: age, BMI, and up to another seven confounders, Figure 5A; aOR 1.03, 95% CI 1.02–1.04, \(k = 2\), adjusted for: age, BMI, family history of diabetes, plus eight confounders, Figure 5B).\(^{69,99}\) There was no statistical heterogeneity between studies for either analysis (both \(I^2 = 0\%\), \(P_{\text{het}} > 0.1\)).

### 3.3.4 | Fasting plasma glucose

Seventeen cohort, three nested case-control and two retrospective analyses provided data on FPG.\(^{24,48,53,60–62,65,72,73,85,97,98,101,102,104–111}\) Sample sizes ranged from 106 to 17,736 participants. Overall, women with GDM had a mean 0.41 mmol/L higher FPG during early pregnancy compared to women without GDM (\(p < 0.001\); Supplementary Figure S4).\(^{48,53,60,61,65,101,102,106,107,111}\)

Nine studies comprising eight unique samples were included in the meta-analysis.\(^{53,60,62,72,73,97,104,105}\) Increased FPG in early pregnancy was associated with a higher odds for GDM (unadjusted OR 2.04; 95% CI 1.37–3.04, \(k = 6\), Figure 6A; adjusted for: age, BMI, and up to seven other confounders, OR 1.92; 95% CI 1.39–2.64, \(k = 7\), Figure 6B).

### 3.3.5 | Glycosylated haemoglobin (HbA1c)

Eight cohort, one case-control, and one randomised controlled trial measured HbA1c in blood samples collected at the first antenatal visit.\(^{60,61,93,101,106,112–116}\) Sample sizes ranged from 142 to 2275 participants. Women who developed GDM had 0.20% higher mean HbA1c in early pregnancy compared to women without GDM (\(p < 0.0001\); Supplementary Figure S5).\(^{60,61,93,101,106,112–114}\) Three studies were used in the meta-analysis,\(^{61,93,103}\) demonstrating an association between HbA1c and GDM (adjusted OR 3.88; 95% CI 1.30–11.60, \(k = 3\); Figure 7, \(I^2 = 49\%\), \(P_{\text{het}} = 0.14\)).
**FIGURE 4** Meta-analysis of early pregnancy obesity and odds of gestational diabetes. Values are odds ratios (OR) with 95% confidence intervals (CIs) for (A) unadjusted analysis and (B) adjusted for maternal age. For overall effect, \( p \)-value <0.05 was considered significant.

**FIGURE 5** Meta-analysis of blood pressure during early pregnancy and odds of gestational diabetes. Values are odds ratios (OR) with 95% confidence intervals (CIs) for (A) raised blood pressure (systolic blood pressure >130 mm Hg or diastolic blood pressure >85 mm Hg) and (B) systolic blood pressure; adjusted for maternal age, BMI, family history, and ethnicity. For overall effect, \( p \)-value <0.05 was considered significant.
3.3.6 | Triglycerides

Thirteen cohort and three nested case-control studies measured fasting TG in early pregnancy. Sample sizes ranged from 107 to 15,194 participants. Women who developed GDM had higher TG measured in early pregnancy compared to women who did not develop GDM (mean difference 0.24 mmol/L, $p < 0.00001$; Supplementary Figure S6). Six studies were included in the meta-analysis. Increasing TG was associated with 1.19-fold increased likelihood for GDM in analyses adjusted for age, BMI and up to another seven confounders (95% CI 0.95–1.48, Figure 8A) with high statistical heterogeneity between studies ($I^2 = 94\%$, $p_{\text{het}} < 0.00001$, $k = 4$). Triglycerides $>1.7\text{ mmol/L}$ was also associated with higher likelihood of GDM (adjusted OR 1.92; 95% CI 1.30–2.85, $I^2 = 0\%$, $p_{\text{het}} = 0.73$, $k = 2$; Figure 8B).

3.3.7 | High-density lipoprotein cholesterol (HDL-C)

Eight cohort and 2 nested case-control studies reported on fasting HDL-C in early pregnancy. Sample sizes ranged...
from 333 to 5218. Women with GDM had slightly lower mean HDL-C compared to women without GDM (Supplementary File 2). On meta-analysis, there was insufficient evidence to confirm an association between HDL-C and GDM (aOR 0.57, 95% CI 0.14–2.32, $I^2 = 92\%$, $P_{het} = 0.0004$, $k = 2$; Figure 9A), but an HDL-C of <1.3 mmol/L was associated with higher odds of GDM (aOR 1.27; 95% CI 1.06–1.51, $I^2 = 0\%$, $P_{het} = 0.60$, $k = 2$; Figure 9B).

### 3.3.8 Metabolic syndrome

Three prospective cohort studies with a sample size ranging from 498 to 3126 were pooled in the meta-analysis. Metabolic syndrome in early pregnancy was associated with a higher odds of GDM in unadjusted (OR 2.58, 95% CI 1.97–3.37, $I^2 = 0\%$, $P_{het} = 0.51$, $k = 2$; Figure 10A) and adjusted analyses for age, BMI and up to another 7 confounders (aOR 2.52, 95% CI 1.65–3.84, $I^2 = 67\%$, $P_{het} = 0.05$, $k = 3$; Figure 10B).

### 3.3.9 Heterogeneity

Sensitivity analyses were performed on adjusted analyses for BMI (continuous and categorical), FPG, and TG (Supporting Information, Figures S8–S12). Removing the studies with high risk of bias marginally reduced the likelihood of GDM in obese women but did not alter the OR or statistical heterogeneity for the other metabolic factors examined. Excluding the outlier studies with a different direction of effect estimate, the statistical heterogeneity became insignificant for BMI as a continuous variable, and marginally increased the adjusted odds ratio for the effect of TG on GDM. When exploring heterogeneity among the obese BMI category, separately eliminating each study with a large effect estimate did not change the odds of GDM or statistical heterogeneity; however, when removing the three studies together, odds for GDM was reduced, with a moderate, albeit statistically significant change in heterogeneity. There were insufficient numbers of studies to perform sub-group analyses according to GDM criteria within any metabolic factor (Supporting information Figure S13).

### 4 DISCUSSION

#### 4.1 Principal findings

The purpose of this systematic review and meta-analysis was to examine the association between maternal MetS and its components with GDM, an independent risk factor for future type 2 diabetes and CVD. Women with overweight or obesity had up to a 4-fold increased risk for GDM, and increasing FPG or having the MetS as a clustering of factors posed up to a 2.5 times higher likelihood for developing GDM. Findings were consistent in adjusted analyses and persisted in sensitivity analyses to reduce heterogeneity.

#### 4.2 Strengths and limitations

Strengths of this review include the extensive and thorough literature search to retrieve relevant eligible studies. The intention to
investigate prognostic factors is critically different to prediction models which are used to predict the risk of current disease presence and outcome occurrence in individuals, thereby informing clinical diagnosis. Prognostic research may have an important impact on the translation of interventions from research to clinical practice, to inform health policy and improve patient outcomes. Limitations of the literature reviewed include the overall general moderate or high risk of bias of included studies, mainly because of the lack of adjustment for confounding factors or poor methods of reporting of statistical analyses. The criteria used for diagnosing GDM varied across the included studies, and several studies did not specify how the diagnosis was made. Meta-analyses also have inherent weaknesses in terms of combining heterogeneous data sets. There was high heterogeneity ($I^2 > 50\%$) for the pooled adjusted analyses for BMI as a continuous or categorical variable, and also for glucose. However, removing studies with a high risk of bias did not alter the

**Figure 9** Meta-analysis of early pregnancy high-density lipoprotein cholesterol (HDL-C) and odds of gestational diabetes. (A), Values are odds ratios (OR) with 95% confidence intervals (CIs) for one unit increase in HDL-C adjusted for maternal age and body mass index (BMI). (B), Odds ratio with 95% CI for low HDL-C (<1.3 mmol/l) adjusted for maternal age. For overall effect, p-value <0.05 was considered significant.

**Figure 10** Meta-analysis of early pregnancy metabolic syndrome and odds of gestational diabetes. Values are odds ratios (OR) with 95% confidence intervals (CIs) for (A) unadjusted and (B) adjusted for maternal age, body mass index (BMI) and family history, analyses. For overall effect, p-value <0.05 was considered significant.
effect estimates or heterogeneity, suggesting study quality does not appear to contribute to an overestimation of the magnitude of the effect that these risk factors have on risk for GDM. Comparatively, removing studies with a different direction of effect or with a larger than usual effect size, reduced heterogeneity indicating publication biases apparent. We could not evaluate clinical heterogeneity from the included studies. It is acknowledged that maternal age, BMI and ethnicity are risk factors for GDM. Yet although the studies in our review enrolled younger and older pregnant women or women across the BMI spectrum, the studies did not specifically recruit women who were either younger or older, or with low or high BMI, thus subgroups could not be created. While many studies also included women across different ethnic groups, studies did not always report on the proportion of different ethnicities included, and where they did, they were not sufficiently homogenous across studies to make comparisons. Thus, the effect of age, BMI, or ethnicity, on the strength of the association with GDM could not be determined. Nevertheless, we did find that even after adjusting for age and BMI, the effect of the different MetS risk factors on GDM was similar to unadjusted analyses.

### 4.3 | Comparison with other studies

Women with overweight or obesity had a 2.4-fold greater likelihood for development of GDM. A recent meta-analysis using 33 observational studies demonstrated up to a 3.2-fold increased odds for GDM with increasing pre-pregnancy BMI category, and a 19% increased risk of GDM per unit of increase in pre-pregnancy BMI. Our results for early pregnancy overweight or obesity are in line with findings on pre-pregnancy BMI, albeit, a smaller increase in odds for GDM (8%) per unit increase. Importantly, for our review, we deliberately focussed on early pregnancy BMI, because losing weight before pregnancy does not appear to alter risk for GDM compared to women who are weight stable. Pregnant women with overweight or obesity have higher FPG, insulin, and TG, compared to normal weight pregnant women. However, several of the individual studies in this review demonstrated that metabolic risk factors increased risk for GDM, independent of BMI. Since weight loss is not recommended during pregnancy, and targeting pre-conception women with overweight or obesity is likely to be challenging, our findings reinforce the need to identify other important modifiable risk factors for GDM.

An approximate 2-fold risk for GDM was demonstrated with increasing level of FPG, which persisted in adjusted and sensitivity analyses. Across gestation, glucose levels reduce due to the maternal adaptations of pregnancy and because of the increased glucose utilisation by the foetal-placental unit. There is also an increase in insulin resistance. These maternal adaptations potentially limit the use of fasting glucose in early pregnancy for early diagnosis of GDM. However, there is data to show that maternal hyperglycaemia before the routine diagnosis of GDM increases the rate of foetal growth and infant adiposity. Thus whether to diagnose GDM in early pregnancy is an ongoing point of contention. Our results provide some evidence that testing for early FPG may be useful to intervene in women with high glucose to ameliorate the adverse short and long-term effects of prolonged intrauterine exposure to hyperglycaemia, but the strength of this evidence is insufficient to alter clinical practice or guide timing of early testing. For measurement of HbA1c, a longer-term measure of glucose control, three studies were included in the meta-analysis of which one study had a very small OR with large CIs. Thus, whether HbA1c is useful for early screening of future GDM cannot be established from this analysis and requires further investigation.

Increasing fasting TG was associated with a 1.2-fold increased likelihood for GDM, however from two studies, triglyceride levels >1.7 mmol/L was associated with a 2-fold increased risk. Increased TG are associated with insulin resistance, but not only drives the process for MetS, but also an important factor underlying the development of type 2 diabetes and CVD. In a recent study of 500 adults in China, TG positively correlated with insulin resistance in participants with normal glucose tolerance, with a negative, independent correlation with beta cell function in individuals with dyslipidaemia. Indeed, a clustering of abnormalities (i.e. metabolic syndrome) which is related to insulin resistance and/or hyperinsulinemia coupled with dyslipidaemia, may be unfavourable to GDM and overall cardiometabolic health. Our systematic review identified only three studies investigating MetS, and pooling of these studies showed a 2.5-fold higher likelihood for developing GDM. This odds ratio is higher than the individual risk associated with elevated FPG or TG, but lower to that of obesity. While these observations are important and highlight a potentially important relationship between MetS in early pregnancy and risk for GDM, the studies available were few, warranting further investigation.

### 4.4 | Recommendations or clinical implications

Overall, our review cannot provide explicit recommendations or implications for practice for women who may benefit early screening and assessment of MetS factors to identify potential risk for GDM. While the effect estimates remained largely unchanged in sensitivity analyses, the overall high heterogeneity could not be sufficiently tested given the available data from the studies. Moreover, subgroup analyses in populations at higher risk of GDM, such as older maternal age, higher BMI, and women of minority ethnicities, could not be undertaken. The indication that MetS as a cluster of risk factors demonstrated a doubled risk for GDM, warrants further exploration, both in women with and without obesity.

### 5 | CONCLUSION

The meta-analysis provides some evidence that early pregnancy assessment of FPG or the MetS, as a clustering of factors, offers a potential opportunity to detect and treat individual risk factors as an important approach towards GDM prevention. Women with
overweight or obesity in pregnancy are also at risk for GDM, however weight loss in pregnancy is not recommended. Given the overall number and quality of studies included, there is a need for further, larger, and higher quality studies to corroborate these results.

ACKNOWLEDGEMENTS
We greatly acknowledge the guidance from Dr. Shamil Cooray for the development of the search strategy, and Dr. Rui Wang, for statistical support. Nahal Habibi and Jessica A. Grieger have financial support from the National Health and Medical Research Council (NHMRC) Ideas Grant, awarded to Jessica A. Grieger (GNT 2009038). Aya Mousa is supported by a biomedical research fellowship provided by the NHMRC of Australia (GNT 1161871). CTT holds a scholarship from the Centre of Research Excellence in PCOS and Research Training Program Scholarship from the Commonwealth of Australia.

Open access publishing facilitated by The University of Adelaide, as part of the Wiley - The University of Adelaide agreement via the Council of Australian University Librarians.

CONFLICT OF INTEREST
None to declare.

ETHICS STATEMENT
Ethics approval is not applicable because this study is based exclusively on published literature.

AUTHOR CONTRIBUTIONS
Nahal Habibi: Methodology, Formal analysis, Data Curation, Investigation, Writing - Original Draft, Writing - Review & Editing. Aya Mousa: Data Curation, Investigation, Writing - Review & Editing, Supervision; Chau Thien Tay: Data Curation, Investigation, Writing - Review & Editing, Mahnaz Bahri Khomami: Data Curation, Investigation, Writing - Review & Editing, Rhiannon K. Patten: Data Curation, Investigation, Writing - Review & Editing, Prabha H. Andraweera: Data Curation, Investigation, Writing - Review & Editing, Molla Wasse: Data Curation, Investigation, Writing - Review & Editing, Jared Vandersluis: Data Curation, Investigation, Writing - Review & Editing, Ali Aflatounian: Data Curation, Investigation, Writing - Review & Editing, Tina Bianco-Miotta: Conceptualization, Data Curation, Investigation, Writing - Review & Editing, Shao J. Zhou: Conceptualization, Data Curation, Investigation, Writing - Review & Editing, Supervision. Jessica A. Grieger: Conceptualization, Methodology, Data Curation, Project administration, Funding acquisition, Writing - Review & Editing, Supervision.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available in All data taken from published studies at https://pubmed.ncbi.nlm.nih.gov. These data were derived from the following resources available in the public domain: Pubmed, https://pubmed.ncbi.nlm.nih.gov.

ORCID
Nahal Habibi https://orcid.org/0000-0003-1017-8032
Aya Mousa https://orcid.org/0000-0002-7356-4523
Mahnaz Bahri Khomami https://orcid.org/0000-0002-5955-1283
Rhiannon K. Patten https://orcid.org/0000-0002-1655-1849
Prabha H. Andraweera https://orcid.org/0000-0003-2434-8370
Ali Aflatounian https://orcid.org/0000-0002-9004-6920
Tina Bianco-Miotta https://orcid.org/0000-0002-8431-5338
Shao J. Zhou https://orcid.org/0000-0003-4012-983X
Jessica A. Grieger https://orcid.org/0000-0003-1515-948X

PEER REVIEW
The peer review history for this article is available at https://publons.com/publon/10.1002/dmrr.3532.

REFERENCES
1. Nankervis A, Price S, Conn J. Gestational diabetes mellitus: a pragmatic approach to diagnosis and management. Aust J Gen Pract. 2018;47(7):445-449. https://doi.org/10.3112/AJGP-01-18-4479
2. International Diabetes Federation. IDF Diabetes Atlas. In: 9th Edn. Ed. Brussels, Belgium; 2019. https://www.diabetesatlas.org/; https://www.diabetesatlas.org/
3. Benhalima K, Van Crombrugge P, Moynson C, et al. Characteristics and pregnancy outcomes across gestational diabetes mellitus subtypes based on insulin resistance. Diabetologia. 2019;62(11):2118-2128. https://doi.org/10.1007/s00125-019-4961-7
4. Bryson CL, Ioannou GN, Rulyak SJ, Critchlow C. Association between gestational diabetes and pregnancy-induced hypertension. Am J Epidemiol. 2003;158(12):1148-1153. https://doi.org/10.1093/aje/kwg273
5. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes. A systematic review. 2002;25(10):1862-1868. https://doi.org/10.2337/diacare.25.10.1862
6. Kramer CK, Campbell S, Retnakaran R. Gestational diabetes and the risk of cardiovascular disease in women: a systematic review and meta-analysis. Diabetologia. 2019;62(6):905-914. https://doi.org/10.1007/s00125-019-4840-2
7. Hapo Study Cooperative Research Group, Metzger BE, Lowe LP, Contreras M, Sacks DA, Watson W, Dooley SL. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008;358(19):1991-2002. https://doi.org/10.1056/NEJMoa0707943
8. Ornoy A. Prenatal origin of obesity and their complications: gestational diabetes, maternal overweight and the paradoxical effects of fetal growth restriction and macrosomia. Reprod Toxicol. 2011;32(2):205-212. https://doi.org/10.1016/j.reprotox.2011.05.002
9. Young BC, Ecker JL. Fetal macrosomia and shoulder dystocia in women with gestational diabetes: risks amenable to treatment? Curr Diabetes Rep. 2013;13(1):12-18. https://doi.org/10.1007/s11892-012-0338-8
10. Landon MB, Spong CY, Thom E, et al. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med. 2009;361(14):1339-1348. https://doi.org/10.1056/NEJMoa0902430
11. Harris DL, Weston PJ, Signal M, Chase JG, Harding JE. Dextrose gel for neonatal hypoglycaemia (the Sugar Babies Study): a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382(9910):2077-2083. https://doi.org/10.1016/S0140-6736(13)61645-1
12. Dabelea D. The predisposition to obesity and diabetes in offspring of diabetic mothers. *Diabetes Care*. 2007;30(Suppl 2):S169-S174. https://doi.org/10.2337/dc07-S211

13. Boney CM, Verma A, Tucker R, Vohr BR. Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus. *Pediatrics*. 2005;115(3):e290-e296. https://doi.org/10.1542/peds.2004-1808

14. Rosenberg TJ, Garbers S, Lipkind H, Chiasson MA. Maternal obesity and diabetes as risk factors for adverse pregnancy outcomes: differences among 4 racial/ethnic groups. *Am J Publ Health*. 2005;95(9):1545-1551. https://doi.org/10.2105/AJPH.2005.0506580

15. Teh WT, Teede HJ, Paul E, Harrison CL, Wallace EM, Allan C. Maternal lipid profile and the relation with spontaneous preterm delivery: a systematic review. *Arch Gynecol Obstet*. 2017;295(2):313-323. https://doi.org/10.1007/s00404-016-4216-5

16. Ryczek KK, Spracklen CN, Smith CJ, Robinson JG, Saftlas AF. Maternal lipid levels during pregnancy and gestational diabetes: a systematic review and meta-analysis. *BJOG*. 2015;122(5):643-651. https://doi.org/10.1111/1471-0528.13261

17. Thom G, Lean M. Is there an optimal diet for weight management and metabolic health? *Gastroenterology*. 2017;152(7):1739-1751. https://doi.org/10.1053/j.gastro.2017.01.056

18. Wang Y, Xu D. Effects of aerobic exercise on lipids and lipoproteins. *Lipids Health Dis*. 2017;16(1):132. https://doi.org/10.1186/s12944-017-0515-8

19. Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus—mechanisms, management, and clinical considerations. *Circulation*. 2016;133(24):2459-2502. https://doi.org/10.1161/circulationaha.116.022194

20. Donovan BM, Nidey NL, Jasper EA, et al. First trimester prenatal screening biomarkers and gestational diabetes mellitus: a systematic review and meta-analysis. *PLoS One*. 2018;13(7):e0201319. https://doi.org/10.1371/journal.pone.0201319

21. Yao D, Chang Q, Wu Q-J, et al. Relationship between maternal central obesity and the risk of gestational diabetes mellitus: a systematic review and meta-analysis of cohort studies. *J Diabetes Res*. 2020;2020:6303820. https://doi.org/10.1155/2020/6303820

22. Lamain-de Ruiter M, Kwee A, Naaktgeboren CA, Franx A, Moons KGM, Koster MPH. Prediction models for the risk of gestational diabetes: a systematic review. *Diagn Prognostic Res*. 2017;1:3. https://doi.org/10.1186/s41512-016-0005-7

23. Lorenzo-Almorós A, Han G, Peiró C, et al. Predictive and diagnostic biomarkers for gestational diabetes and its associated metabolic and cardiovascular diseases. *Cardiovasc Diabetol*. 2019;18(1):140. https://doi.org/10.1186/s12933-019-0935-9

24. Shepherd E, Gomersall JC, Tieu H, Sanders K, Coster WA. Combined diet and exercise interventions for preventing gestational diabetes mellitus. *Cochrane Database Syst Rev*. 2017(11). https://doi.org/10.1002/14651858.CD004443.pub3

25. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ Clin Res ed*. 2021;372:n71. https://doi.org/10.1136/bmj.n71

26. Geersing GJ, Bouwmeester W, Zuithoff P, Spijker R, Leeflang MM, Koster MPH. Prediction models for the risk of gestational diabetes. *Rev Endocr Metabol Disord*. 2017;18(8):305. https://doi.org/10.1007/s11392-017-0515-4

27. Almorós A, Hang T, Peiró C, et al. Predictive and diagnostic biomarkers for gestational diabetes and its associated metabolic and cardiovascular diseases. *Cardiovasc Diabetol*. 2019;18(1):140. https://doi.org/10.1186/s12933-019-0935-9

28. Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. *Diabetes Care*. 2008;31(9):1898-1904. https://doi.org/10.2337/dc08-0423

29. Grieger JA, Bianco-Miotto T, Grzeskowiak LE, et al. Metabolic syndrome in pregnancy and risk for adverse pregnancy outcomes: a prospective cohort of nulliparous women. *PLoS Med*. 2018;15(12):e1002710. https://doi.org/10.1371/journal.pmed.1002710

30. Schneider AK, Leemaz SY, Dalton J, et al. The interaction between metabolic syndrome and physical activity, and risk for gestational diabetes mellitus. *Acta Diabetol*. 2021;58(7):939-947. https://doi.org/10.1007/s00592-021-01696-9

31. Barrett HL, Dekker Niter M, McIntyre HD, Callaway LK. Normalizing metabolism in diabetic pregnancy: is it time to target lipids? *Diabetes Care*. 2014;37(5):1484-1493. https://doi.org/10.2337/dc13-1934

32. Moayyeri M, Heida KY, Franx A, Spiering W, de Laat MW, Oudijk MA. Maternal lipid profile and the relation with spontaneous preterm delivery: a systematic review. *Arch Gynecol Obstet*. 2017;295(2):313-323. https://doi.org/10.1007/s00404-016-4216-5
44. Langan D, Higgins JPT, Jackson D, et al. A comparison of heterogeneity variance estimators in simulated random-effects meta-analyses. *Res Synth Methods*. 2019;10(1):83-98. https://doi.org/10.1002/jrsm.1316

45. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. 2003;327(7414):557-560. https://doi.org/10.1136/bmj.327.7414.557

46. Patsopoulos NA, Evangelou E, Ioannidis JP. Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. *Int J Epidemiol*. 2008;37(5):1148-1157. https://doi.org/10.1093/ije/dyn065

47. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. *J Clin Epidemiol*. 2000;53(11):1119-1129. https://doi.org/10.1016/s0895-4356(00)00242-0

48. Sánchez-Vera I, Bonet B, Viana M, et al. Changes in plasma lipids and increased low-density lipoprotein susceptibility to oxidation in pregnancies complicated by gestational diabetes: consequences of obesity. *Metabolism*. 2007;56(11):1527-1533. https://doi.org/10.1016/j.metabol.2007.06.020

49. Doi L, Williams AJ, Marryat L, Frank J. Cohort study of high maternal body mass index and the risk of adverse pregnancy and delivery outcomes in Scotland. *BMJ Open*. 2020;10(2):e026168. https://doi.org/10.1136/bmjopen-2018-026168

50. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. *Diabetes Care*. 2010;33(3):676-682. https://doi.org/10.2337/dc09-1848

51. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus; 1999. https://apps.who.int/anr/iris/handle/10665/66040

52. Carpenter MW, Coustan DR. Criteria for screening tests for gestational diabetes. *Am J Obstet Gynecol*. 1982;144(7):768-773. https://doi.org/10.1016/0002-9378(82)90349-0

53. Wani K, Sabico S, Almnaami AM, et al. Early-pregnancy metabolic syndrome and subsequent incidence in gestational diabetes mellitus in Arab women. *Front Endocrinol (Lausanne)*. 2020;11:98. https://doi.org/10.3389/fendo.2020.00098

54. Zhu Y, Heddenson MM, Quesenberry CP, Feng J, Ferrara A. Central obesity increases the risk of gestational diabetes partially through increasing insulin resistance. *Obes (Silver Spring)*. 2019;27(1):152-160. https://doi.org/10.1002/oby.22339

55. Han Q, Shao P, Leng J, et al. Interactions between general and central obesity in predicting gestational diabetes mellitus in Chinese pregnant women: a prospective population-based study in Tianjin, China. *J Diabetes*. 2018;10(1):59-67. https://doi.org/10.1007/111753-0407.12558

56. Hancerliogullari N, Kansu-Celik H, Aslı Oskovi-Kaplan Z, Kisa B, Engin-Ustun Y, Ozgu-Erdinc AS. Optimal maternal neck and waist circumference cutoff values for prediction of gestational diabetes mellitus at the first trimester in Turkish women: a prospective cohort study. *Gynecol Endocrinol*. 2020;36(11):1002-1005. https://doi.org/10.1080/09513539.2020.1750003

57. Alptekin H, Çizmecioglu A, Isik H, Cengiz T, Yildiz M, Ilyisoy MS. Predicting gestational diabetes mellitus during the first trimester using anthropometric measurements and HOMA-IR. *J Endocrinol Invest*. 2016;39(5):577-583. https://doi.org/10.1007/s40618-015-0427-z

58. Gao S, Leng J, Liu H, et al. Development and validation of an early pregnancy risk score for the prediction of gestational diabetes mellitus in Chinese pregnant women. *BMJ Open Diabetes Res Care*. 2020;8(1):e000909. https://doi.org/10.1136/bmjdrca-2019-000909

59. Basraon SK, Mele L, Myatt L, et al. Relationship of early pregnancy waist-to-hip ratio versus body mass index with gestational diabetes mellitus and insulin resistance. *Am J Perinatol*. 2016;33(1):114-121. https://doi.org/10.1055/s-0035-1562928

60. Falcone V, Kotzaeridi G, Breil MH, et al. Early assessment of the risk for gestational diabetes mellitus: can fasting parameters of glucose metabolism contribute to risk prediction? *Diabetes Metab J*. 2019;43(6):785-793. https://doi.org/10.4093/dmj.2018.0218

61. Kumru P, Arisyos R, Erdogdu E, et al. Prediction of gestational diabetes mellitus at first trimester in low-risk pregnancies. *Taiwan J Obstet Gynecol*. 2016;55(6):815-820. https://doi.org/10.1016/j.tjog.2016.04.032

62. Li P, Lin S, Li L, Cui J, Zou S, Fan J. First-trimester fasting plasma glucose as a predictor of gestational diabetes mellitus and the association with adverse pregnancy outcomes. *Pak J Med Sci*. 2019;35(1):95-100. https://doi.org/10.10266/pjms.35.1.216

63. Liu PJ, Liu Y, Ma L, et al. The predictive ability of two triglyceride-associated indices for gestational diabetes mellitus and large for gestational age infant among Chinese pregnancies: a preliminary cohort study. *Diabetes Metab Syndr Obes*. 2020;13:2025-2035. https://doi.org/10.2147/dmso.s251846

64. Li G, Huang W, Zhang L, et al. A prospective cohort study of early-pregnancy risk factors for gestational diabetes mellitus in polycystic ovarian syndrome. *Diabetes/Metabol Res Rev*. 2018;34(5):e3003. https://doi.org/10.1002/dmrr.3003

65. Pazhohnan A, Rezaee Moradali M, Pazhohnan N. Association of first-trimester maternal lipid profiles and triglyceride-glucose index with the risk of gestational diabetes mellitus and large for gestational age newborn. *J Matern Fetal Neonatal Med*. 2019;32(7):1167-1175. https://doi.org/10.1080/14767058.2017.1402876

66. Savvidou D, Nelson SM, Makkaba G, Messow CM, Sattar N, Nicolaides KH. Prediction of gestational diabetes mellitus by maternal factors and biomarkers at 11 to 13 weeks. *Prenat Diagn*. 2011;31(2):135-141. https://doi.org/10.1002/pd.2636

67. Syngelaki A, Bredaki FE, Vaikousi E, Maiz N, Nicolaides KH. Body mass index at 11-13 weeks’ gestation and pregnancy complications. *Fetal Diagn Ther*. 2011;30(4):250-265. https://doi.org/10.1159/000328083

68. Gabbay-Benziv R, Doyle LE, Blitzer M, Baschat AA. First trimester prediction of maternal glycemic status. *J Perinat Med*. 2015;43(3):283-289. https://doi.org/10.1515/jpm-2014-0149

69. Sánchez-Garcia A, Rodríguez-Gutiérrez R, Saldívar-Rodríguez D, et al. Early triglyceride and glucose index as a risk marker for gestational diabetes mellitus. *Int J Gynaecol Obstet*. 2020;171(1):117-123. https://doi.org/10.1002/ijgo.13311

70. SweETING AN, Appelblom H, Ross GP, et al. First trimester prediction of gestational diabetes mellitus: a clinical model based on maternal demographic parameters. *Diabetes Res Clin Pract*. 2017;127:44-50. https://doi.org/10.1016/j.diabres.2017.02.036

71. Riskin-Mashiah S, Damti A, Younes G, Auslander R. First trimester fasting hyperglycemia as a predictor for the development of gestational diabetes mellitus. *Eur J Obstet Gynecol Reprod Biol*. 2010;152(2):163-167. https://doi.org/10.1016/j.ejogrb.2010.05.036

72. Yachi Y, Tanaka Y, Anasako Y, Nishibata I, Saito K, Sone H. Contribution of first trimester fasting plasma insulin levels to the incidence of glucose intolerance in later pregnancy: Tanaka Women’s Clinic Study. *Diabetes Res Clin Pract*. 2011;92(2):293-298. https://doi.org/10.1016/j.diabres.2011.02.012

73. Migda M, Migda MS, Migda B, Krzyżanowska P, Wender-Ożegowska E. Components of metabolic syndrome in the first
trimester of pregnancy as predictors of adverse perinatal outcome. Gynecol Pol. 2016;87(9):644-650. https://doi.org/10.5603/gp.2016.0060

75. Cozzolino M, Serena C, Maggio L, et al. Analysis of the main risk factors for gestational diabetes diagnosed with International Association of Diabetes and Pregnancy Study Groups (IADPSG) criteria in multiple pregnancies. J Endocrinol Invest. 2017;40(9):937-943. https://doi.org/10.1007/s40618-017-0646-6

76. Farah N, McGoldrick A, Fattah C, O’Connor N, Kennelly MM, Turner MJ. Body mass index (BMI) and glucose intolerance during pregnancy in white European women. J Reproduction Infertil. 2012;13(2):95-99.

77. Teede HJ, Harrison CL, Teh WT, Paul E, Allan CA. Gestational diabetes: development of an early risk prediction tool to facilitate opportunities for prevention. Aust N Z J Obstet Gynaecol. 2011;51(6):499-504. https://doi.org/10.1111/j.1475-928X.2011.01356.x

78. Collier A, Abraham EC, Armstrong J, Godwin J, Monteketh C, Lindsay R. Reported prevalence of gestational diabetes in Scotland: the relationship with obesity, age, socioeconomic status, smoking and macrosomia, and how many are we missing? J Diabetes Investig. 2017;8(2):161-167. https://doi.org/10.1111/jdi.12552

79. Knight-Agarwal CR, Williams LT, Davis D, et al. Association between maternal and interpregnancy BMI change with birth outcomes in an Australian obstetric population: a retrospective cohort study. BMJ Open. 2016;10(6):1. https://doi.org/10.1136/bmjopen-2015-010667

80. Raja UA, McAreer T, Bassett P, Sharma S. The implications of a raised maternal BMI: a DGH experience. J Obstet Gynaecol. 2012; 32(3):247-251. https://doi.org/10.3109/01443615.2011.645920

81. El-Gilany AH, Hammed S. Body mass index and obstetric outcomes in pregnancy in Saudi Arabia: a prospective cohort study. Ann Saudi Med. 2010;30(5):376-380. https://doi.org/10.4103/0256-4947.67075

82. Schrauwers C, Dekker G. Maternal and perinatal outcome in obese pregnant patients. J Matern Fetal Neonatal Med. 2009;22(3):218-226. https://doi.org/10.1080/1476705090281652

83. Phaloprakarn C, Tangjitgamol S, Manusirivithaya S. A risk score for selective screening for gestational diabetes mellitus. Eur J Obstet Gynecol Reprod Biol. 2009;145(1):71-75. https://doi.org/10.1016/j.ejogrb.2009.04.016

84. Denison F, Norwood P, Bhattacharya S, et al. Association between maternal body mass index during pregnancy, short-term morbidity, and increased health service costs: a population-based study. BJOG Int J Obstet Gynaecol. 2014;121(1):72-82. https://doi.org/10.1111/1471-0528.12443

85. Lei Q, Niu J, Lv L, et al. Clustering of metabolic risk factors and adverse pregnancy outcomes: a prospective cohort study. Diabetes Metabol Res Rev. 2016;32(8):835-842. https://doi.org/10.1002/dmrr.2803

86. Magann EF, Doherty DA, Lin AT, Chauhan SP, Morrison JC. The effects of an increasing gradient of maternal obesity on pregnancy outcomes. Aust N Z J Obstet Gynaecol. 2013;53(3):250-257. https://doi.org/10.1111/ajo.12047

87. Simko M, Totka A, Vondrova D, et al. Maternal body mass index and gestational weight gain and their association with pregnancy complications and perinatal conditions. Int J Environ Res Publ Health. 2019;16(10):1751. https://doi.org/10.3390/ijerph16101751

88. Zhao YN, Li Q, Li YC. Effects of body mass index and body fat percentage on gestational complications and outcomes. J Obstet Gynaecol Res. 2014;40(3):705-710. https://doi.org/10.1011/jog.12240

89. Hashemi-Nazari S-S, Najaf F, Rahimi M-A, Izadi N, Heydarpour F, Forooghheid H. Estimation of gestational diabetes mellitus and dose–response association of BMI with the occurrence of diabetes mellitus in pregnant women of the west of Iran. Health Care Women Int. 2020;41(1):121-130. https://doi.org/10.1080/07399332.2018.1521812

90. Seiddee C, Valsaraj BP, Pais M. A correlative study to assess the effect of first trimester BMI on obstetric outcome. Int J Nurs Educ Scholarsh. 2012;4(1):35-36.

91. Yang Z, Phung H, Freebairn L, Sexton R, Raulli A, Kelly P. Contribution of maternal overweight and obesity to the occurrence of adverse pregnancy outcomes. Aust N Z J Obstet Gynaecol. 2019;59(3):367-374. https://doi.org/10.1111/ajo.12866

92. Zheng W, Huang W, Zhang L, et al. Early pregnancy metabolic factors associated with gestational diabetes mellitus in normal-weight women with polycystic ovary syndrome: a two-phase cohort study. Diabetol Metab Syndrome. 2019;11(1):71. https://doi.org/10.1186/s13098-019-0462-6

93. Berggren EK, Boggess KA, Mathew L, Culhane J. First trimester maternal glycated hemoglobin and sex hormone-binding globulin do not predict third trimester glucose intolerance of pregnancy. Reprod Sci. 2017;24(4):613-618. https://doi.org/10.1177/193371911667230

94. Iyoke CA, Ugwu GO, Ezugwu FO, Lawani OL, Onyebuchi AK. Retrospective cohort study of the effects of obesity in early pregnancy on maternal weight gain and obstetric outcomes in an obstetric population in Africa. Int J Womens Health. 2013;5:501-507. https://doi.org/10.2147/ijwh.s49909

95. MadHAVAN A, Beena Kumari R, Sanal MG. A pilot study on the usefulness of body mass index and waist hip ratio as a predictive tool for gestational diabetes in Asian Indians. Gynecol Endocrinol. 2008;24(12):701-707. https://doi.org/10.1080/09513550802444134

96. Wolfe HM, Zador IE, Gross TL, Martin SS, Sokol RJ. The clinical utility of maternal body mass index in pregnancy. Am J Obstet Gynecol. 1999;164(5 Pt 1):1306-1310. https://doi.org/10.1016/S0002-9378(99)00705-v

97. Ozgu-Erdinc AS, Yilmaz S, Yeral M, Seckin KD, Erkaya S, Danisman AN. Prediction of gestational diabetes mellitus in the first trimester: comparison of C-reactive protein, fasting plasma glucose, insulin and insulin sensitivity indices. J Matern Fetal Neonatal Med. 2015;28(16):1957-1962. https://doi.org/10.3109/14767058.2014.973397

98. Al-Shafei AI, Raja S, Mohieldin AH, El-Gendy OA, Adam I. Maternal early pregnancy serum level of 25-Hydroxyvitamin D and risk of gestational diabetes mellitus. Int J Gynecol Obstet. 2021;152(3):382-385. https://doi.org/10.1002/ijgo.13389

99. Leng J, Shao P, Zhang C, et al. Prevalence of gestational diabetes mellitus and its risk factors in Chinese pregnant women: a prospective population-based study in Tianjin, China. PLoS One. 2015;10(3):e0121029. https://doi.org/10.1371/journal.pone.0121029

100. Tenenbaum-Gavish K, Sharabi-Nov A, Binyamin D, et al. First trimester biomarkers for prediction of gestational diabetes mellitus. Placenta. 2020;101:80-89. https://doi.org/10.1016/j.placenta.2020.08.020

101. Zhang X, Zhao X, Huo L, et al. Risk prediction model of gestational diabetes mellitus based on nomogram in a Chinese population cohort study. Sci Rep. 2020;10(1):21223. https://doi.org/10.1038/s41598-020-78164-x

102. Kouhkan A, Khamseh ME, Moini A, et al. Predictive factors of gestational diabetes mellitus in pregnancies following assisted reproductive technology: a nested case–control study. Arch Gynecol Obstet. 2018;298(1):199-206. https://doi.org/10.1007/s00404-018-4772-y

103. Godwin M, Muirhead M, Huyhn J, Helt B, Gummer J. Prevalence of gestational diabetes mellitus among Swampy Cree women in
moose factory, James Bay. *CMAJ* (Can Med Assoc J). 1999;160(9):1299-1302.

104. Guo F, Yang S, Zhang Y, Yang X, Zhang C, Fan J. Nomogram for prediction of gestational diabetes mellitus in urban, Chinese, pregnant women. *BMC Pregnancy Childbirth.* 2020;20(43). https://doi.org/10.1186/s12884-019-2703-y

105. Meek CL, Lindsay RS, Scott EM, et al. Approaches to screening for hyperglycaemia in pregnant women during and after the COVID-19 pandemic. *Diabet Med.* 2021;38(1):e14380. https://doi.org/10.1111/dme.13438

106. Kansu-Cellik H, Ozgu-Erdinc AS, Kisa B, Eldem S, Hancerliogullari N, Engin-Ustun Y. Maternal serum glycosylated hemoglobin and fasting plasma glucose predicts gestational diabetes at the first trimester in Turkish women with a low-risk pregnancy and its relationship with fetal birth weight: a retrospective cohort study. *J Matern Fetal Neonatal Med.* 2019;12:1-8. https://doi.org/10.1080/14767058.2019.1651837

107. Wang C, Zhu W, Wei Y, et al. The predictive effects of early pregnancy lipid profiles and fasting glucose on the risk of gestational diabetes mellitus stratified by body mass index. *J Diabetes Res.* 2016;2016:3013567. https://doi.org/10.1155/2016/3013567

108. Gur EB, Ince O, Turan GA, et al. Ultrasonographic visceral fat thickness in the first trimester can predict metabolic syndrome and gestational diabetes mellitus. *Endocrine.* 2014;47(2):478-484. https://doi.org/10.1007/s12020-013-0154-1

109. Zhu WW, Yang HX, Wei YM, et al. Evaluation of the value of fasting plasma glucose in the first prenatal visit to diagnose gestational diabetes mellitus in China. *Diabetes Care.* 2013;36(3):586-590. https://doi.org/10.2337/dc12-1157

110. Semsilo G, Prats P, Garcia S, et al. First-trimester fasting glycemia as a predictor of gestational diabetes (GDM) and adverse pregnancy outcomes. *Acta Diabetol.* 2019;57(6):697-703. https://doi.org/10.12669/pjms.35.1.2126

111. Ognoskwi M, Miazgowski T, Homa K, Celewicz K, Kuczyńska M. Changes in maternal blood glucose and lipid concentrations during pregnancy differ by maternal body mass index and are related to birthweight: a prospective, longitudinal study of healthy pregnancies. *PLoS One.* 2015;10(5):e0232749. https://doi.org/10.1371/journal.pone.0232749

112. Kapadia MZ, Park CK, Beyene J, Giglia L, Maxwell C, McDonald SD. Weight loss instead of weight gain within the guidelines in obese women during pregnancy: a systematic review and meta-analyses of maternal and infant outcomes. *PLoS One.* 2015;10(7):e0132650. https://doi.org/10.1371/journal.pone.0132650

113. Di Cianni G, Miccoli R, Volpe L, Lencioni C, Del Prato S. Intermediate metabolism in normal pregnancy and in gestational diabetes. *Diabetes Metab Res Rev.* 2003;19(4):259-270. https://doi.org/10.1002/dmr.390

114. Newbourn D, Freemark M. Placental hormones and the control of maternal metabolism and fetal growth. *Curr Opin Endocrinol Diabetes.* 2011;18(6):409-416. https://doi.org/10.1097/MED.0b013e32834c800d

115. Sovio U, Murphy HR, Smith GC. Accelerated fetal growth prior to delivery in women with gestational diabetes. *Am J Obstet Gynecol.* 2017;209:416.e1-416.e10. https://doi.org/10.1016/j.ajog.2017.06.036

116. Amylidi S, Mosimann B, Stettler C, Fiedler GM, Surbek D, Raio L. Lifestyle factors in pregnancy lipid profiles and pregnancy outcomes. *Lipids Health Dis.* 2016;15:98. https://doi.org/10.1186/s12902-015-0039-9

117. Wang C, Zhu W, Wei Y, et al. The associations between pregnancy lipid profiles and pregnancy complications and perinatal outcomes: a population-based study from China. *BMC Pregnancy Childbirth.* 2016;16:1-9. https://doi.org/10.1186/s12884-016-0852-9

118. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals.
Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? *JAMA*. 1990;263(21):2893-2898. https://doi.org/10.1001/jama.263.21.2893

134. Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development. *Nat Rev Endocrinol*. 2014;10(5):293-302. https://doi.org/10.1038/nrendo.2014.29

135. Vergès B. Pathophysiology of diabetic dyslipidaemia: where are we? *Diabetologia*. 2015;58(5):886-899. https://doi.org/10.1007/s00125-015-3525-8

136. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of β-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. *Diabetes Care*. 2006;29(5):1130-1139. https://doi.org/10.2337/dc05-2179

**SUPPORTING INFORMATION**

Additional supporting information can be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Habibi N, Mousa A, Tay CT, et al. Maternal metabolic factors and the association with gestational diabetes: a systematic review and meta-analysis. *Diabetes Metab Res Rev*. 2022;38(5):e3532. https://doi.org/10.1002/dmrr.3532